Western University

Scholarship@Western
Electronic Thesis and Dissertation Repository
9-27-2017 1:30 PM

An invasive tumor cell subpopulation as a therapeutic target in
breast cancer
Tahereh Vakili, The University of Western Ontario
Supervisor: Dr. Eva Turley, The University of Western Ontario
A thesis submitted in partial fulfillment of the requirements for the Master of Science degree in
Biochemistry
© Tahereh Vakili 2017

Follow this and additional works at: https://ir.lib.uwo.ca/etd
Part of the Medicine and Health Sciences Commons

Recommended Citation
Vakili, Tahereh, "An invasive tumor cell subpopulation as a therapeutic target in breast cancer" (2017).
Electronic Thesis and Dissertation Repository. 5104.
https://ir.lib.uwo.ca/etd/5104

This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted
for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of
Scholarship@Western. For more information, please contact wlswadmin@uwo.ca.

Abstract
Tumor heterogeneity and lack of targeted therapies are major hurdles in triple-negative breast
cancer (TNBC) management. Elevated hyaluronan (HA) is a prognostic factor for poor outcome
in TNBC. The TNBC MDA-MB-231 cell line contains highly metastatic but slow growing
subpopulations that bind high levels of HA. I show these subpopulations express elevated HAS2,
RHAMM and PGA3, and are more resistant to doxorubicin but more sensitive to MEK1 targeted
therapy than parental cells or low HA binding subpopulations. Data bank mining show HAS2,
RHAMM, and PGA3 are significantly associated with chemotherapy-treated BCa. Knockout of
RHAMM using CRISPR/Cas9 gene editing reduced localization of active ERK1/2 to nuclei and
sensitivity to MEK1 targeted therapy. These results show that RHAMM and likely HA are
factors in TNBC subset in susceptibility to MEK inhibition, and that it is a potential biomarker
for TNBC patients with sensitivity to MEK1 therapy.
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Chapter 1

1

« Introduction »

Breast cancer is the leading cause of cancer-related death among women in both advanced and
less developed countries1. In Canada, breast cancer is the third most common cancer, accounting
for 13% of all cancers and 25% of cancers among females. An estimated 26,300 and 230 new
cases of female and male breast cancer, respectively, are expected to be diagnosed in Canada in
20172.
Despite high incidence rates, the female breast cancer mortality rate has substantially declined
since its peak in 1987. The age-standardized mortality rates (ASMR) has dropped 44%, from
41.7 deaths per 100,000 in 1988 to a projected rate of 23.2 deaths per 100,000 in 2017 2. The
downward trend is likely due to a combination of advances in screening or prevention, improved
diagnosis, and more effective treatment protocols.
Breast cancer is comprised of a group of heterogeneous diseases that differ significantly in their
molecular, pathological, and clinical features. Several breast cancer classification systems have
been developed and evolved over many decades, some of which are being used in prognosis and
treatment in clinics and some of which currently are in preclinical development3.

1.1 Histological and Molecular Subtypes of Breast Cancer
Clinically, breast cancer classification is based on tumor histology. It is sub-typed primarily into
in situ carcinoma where the tumor is limited to the epithelial component of the breast, and
invasive/infiltrating carcinoma where the tumor has invaded the stroma. In situ carcinomas are
further categorized by their growth pattern and cytological features into ductal carcinomas
(originating from the inner lining epithelium of the ducts) and lobular carcinomas (originating
from the lobules that supply the ducts with milk). Similar to in situ carcinomas, invasive
carcinomas have been classified into several subtypes. The main subtypes include invasive
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ductal, invasive lobular, ductal lobular, tubular, colloid (mucinous), and medullary. Invasive
ductal carcinoma (IDC) is, by far, the most common form of invasive breast cancer. It accounts
for 55% of breast cancer incidence upon diagnosis and 70-80% of invasive lesions4. IDCs are a
heterogeneous group of tumors classified according to cytoarchitectural features such as nuclear
pleomorphism, glandular/tubule formation, and mitotic rate5. IDC is sub-typed as welldifferentiated (grade 1), moderately-differentiated (grade 2), and poorly-differentiated (grade 3)3,
5

(Figure 1.1). Differentiation describes how much or how little tumor cells look like the normal

cells they came from. Here, well-differentiated IDCs look more like normal ductal cells and tend
to grow and spread more slowly than poorly-differentiated counterparts3.

Figure 1.1. Histological classification of breast cancer.
Histological subtyping, which is most commonly used by clinicians, dissects the heterogeneity found in
breast cancer based on architectural features and growth patterns (Figure reproduced from Malhotra et
al.3).

3

Figure 1.2. Molecular intrinsic classification of breast cancer.
This categorization is not currently used in clinical practice but is more practical in identifying molecular
targets (Figure reproduced from Malhotra et al.3).

While histological subtyping of breast cancer has prognostic value, understanding the molecular
basis for these classifications provides an opportunity to discover molecular targets and predict a
response to them. Molecular subclassification focuses on gene expression signatures. Perou et al.
in 2000, first categorized distinct molecular subtypes based on gene expression profiles into ERpositive luminal-like A and B, basal-like, ErbB2-positive and normal-like subgroups6. More
recent studies identified a new subtype classified as “claudin-low”7, 8 with reduced expression of
Claudin proteins, components of epithelial tight junctions (Figure 1.2). This classification is
based on the intrinsic molecular subtypes of breast cancer identified by microarray analysis of
patient tumor samples6-10.
The above classifications emphasize that breast cancer is not a single entity, but a complex and
heterogeneous disease with distinct molecular and clinical characteristics. Despite the molecular
heterogeneity of breast cancer, histological subtypes remain the mainstay of routine clinical
diagnosis. However, these subtypes are of limited utility, since most of the breast cancers
(approximately 75%) belong to a single subtype, invasive ductal carcinoma (IDC) of no special
type. It has been shown that that combination of molecular/functional biomarkers with clinical
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variables results in a system that is more robust and capable than any one system alone.
Therefore, there is a need for designed genomic based clinical trials to advance the molecular
subtypes to the level of clinical practice.

1.1.1 Triple Negative Breast Cancers
The advancement of "omics technologies" such as genomics and proteomics has provided
exceptional insights into the molecular complexity of breast cancer10-13. Nevertheless, clinical
decisions still rely primarily on the assessment of three markers: the expression of the endocrine
receptors for estrogen (ER) and progesterone (PR) and the aberrant expression of human
epidermal growth factor receptor-2 (HER2; also known as ErbB2). Triple-negative breast cancer
(TNBC) is a clinical designation that applies to all the breast cancer phenotypes lacking
expression of ER, PR, and HER2, and which therefore do not respond to therapies directed
against these receptors. TNBC accounts for approximately 15% of breast cancers cases14. It is
usually aggressive, with higher grade or more frequent lymph node metastasis, and it is usually
more prevalent in younger, pre-menopausal, and especially African-American/Hispanic
women15. TNBC patients also experience higher rates of distant metastases and lower five-year
disease-free survival (DFS) rates than patients with other breast cancer subtypes, despite
showing a better initial response to chemotherapy16. Therefore, with the remarkably high rates of
relapse,

developing improved treatments for TNBC is one of the highest priorities in

current breast cancer research.
TNBC is itself a heterogeneous entity and can further be subclassified based on gene expression
analyses. Thus, improved understanding of the biological characteristics and clinical behaviours
of subtypes within TNBC is necessary for designing of clinical trials and developing
personalized treatments. Lehmann et al.17, using gene expression profiling of 587 TNBC
samples, identified six molecular subtypes; Basal-like 1 (BL1), Basal-like 2 (BL2),
Immunomodulatory (IM), Mesenchymal (M), Mesenchymal stem-like (MSL), and Luminal
androgen receptor (LAR) (Table 1.1).
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Of note, triple-negative (TN) and basal-like (BL) breast cancer definitions have been commonly
used interchangeably to describe breast cancers that do not express ER and PR, and
overexpress/amplify HER2 gene. Despite a significant overlap (approximately 70%) between
TNBC and basal-like breast cancer, gene expression data suggest that these two subtypes are not
equivalent18.
Table 1.1. Microarray classification of TNBC.
Subtypes

Genetic signature

Basal-like 1

Enriched in cell cycle and DNA damage response (ATR–BRCA
pathway) gene

Basal-like 2

Enriched in growth factor signaling pathways (EGF, MET, NGF,
Wnt/β-catenin, IGF-1R), glycolysis, gluconeogenesis, and
myoepithelial markers

Immunomodulatory Enriched in immune cell processes; immune cell signaling such as
TH1/TH2, NK cell, and B cell receptor pathway, cytokine signaling
such as IL-12, and IL-7 pathway, antigen processing/presentation, and
signaling through core immune signal transduction pathways such as
NFKB, TNF, and JAK/STAT signaling
Mesenchymal

Enriched in components of cell motility, cell differentiation, and
growth pathways such as Wnt, anaplastic lymphoma kinase pathway,
and TGF-β signaling, EMT

Mesenchymal stem- Similar to Mesenchymal but low levels of proliferation, and claudins
like

3, 4, and 7 genes, Angiogenesis genes

Luminal androgen

Enriched in androgen receptor gene, displays luminal gene expression

receptor

pattern

Six molecular subtypes of TNBC based on gene expression profiling of 587 TNBC samples17, 19
Abbreviations: DNA, deoxyribonucleic acid; EGFR, epidermal growth factor receptor; EMT,
epithelial-mesenchymal-transition; IGF-1R, insulin-like growth factor I receptor; IL, interleukin; MET,
hepatocyte growth factor; NGF, nerve growth factor.
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1.1.2 Diagnosis and Treatment of TNBC
As mentioned earlier, in spite of the molecular heterogeneity of TNBC, clinical decisions
(diagnosis and treatment) still rely primarily on the presence of the endocrine receptors for
estrogen and progesterone and the aberrant expression of HER2. Immunohistochemistry (IHC) is
currently the main hormone receptor assessment. Based on American Society of Clinical
Oncology/College of American Pathologists (ASCO/CAP) guidelines, ER and PR assays should
be considered positive if at least 1% of tumor cells in the sample demonstrate positive nuclear
staining by immunohistochemistry20. HER2 status is determined by IHC and usually, an
additional fluorescent in situ hybridization (FISH), which assesses HER2 gene amplification, is
used to confirm IHC results21.
Treatment of patients with TNBC has been challenging as this type of tumor does not express
PR, ER, and HER2 receptors, and as a result, cannot be managed with presently targeted
therapies such as the anti-HER2 monoclonal antibody Trastuzumab, and hormonal (endocrine)
therapy. Hormonal therapy includes preventing the production of estrogen and progesterone
and/or blocking their receptors signalling in breast cancer cells. With the lack of FDA approved
targeted therapies available for TNBC, mono- or combination chemotherapy remains the only
systemic treatment option for patients in the neoadjuvant, and adjuvant (the administration of
therapeutic agents before or after the main treatment, respectively), or metastatic settings.

1.1.3 Tumor Heterogeneity: a Hurdle for TNBC Diagnosis and Treatment
TNBC presents a significant challenge for the treatment and management with chemotherapy
mainly because of the vast intertumor and intratumor heterogeneity. Intertumor heterogeneity
refers to heterogeneity between tumors from different patients or different lesions from the same
patient. By contrast, intratumor heterogeneity refers to heterogeneity within one tumor at any
given time. Tumor cells can show three different levels of heterogeneity. Firstly, tumor cells can
contain distinct genetic alterations. Secondly, cells with the same genetic landscape can have
different epigenetic alterations and states of differentiation. Thirdly, tumor cells can be
influenced by a complex and diverse microenvironment generated by stromal cell heterogeneity
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that supports tumor growth, reduces immune surveillance, and impede penetration of therapeutic
drugs.
Decoding the molecular basis of tumor heterogeneity could bring insights to more effective
therapeutic strategies. Therefore, it is necessary to identify prognostic factors that are associated
with poor outcome and are potentially involved in treatment resistance. These factors can be
used as probes to sort tumor cells into distinct and homogeneous subsets for investigating their
responses to treatments.
While both genetic and phenotypic markers are available to characterize tumor heterogeneity,
phenotypic markers can be more informative than genetic changes. The genotype to phenotype
map is not simple and genetic heterogeneity may not translate directly to phenotypic
heterogeneity. Therefore, tumor phenotypes, which reflect genetic diversity as well as
microenvironmental dynamics of the tumor, may provide a powerful diagnostic and prognostic
tool.

1.1.4 Hyaluronan as a Diagnostic and Prognostic Factor in TNBC
Hyaluronan (HA), a polymer of alternating N-acetylglucosamine and glucuronic acid
disaccharides (Figure 1.3), is a suitable prognostic/diagnostic factor for several reasons. First,
elevated production of HA has been shown to provide many different cancer cell lines with drug
resistance22. Second, HA accumulation within breast cancer cells and peritumor stroma is a
predictor of poor outcome23 as well as an indicator of the conversion of the pre-invasive form of
breast cancer, ductal carcinoma in situ, to an early invasive form of breast cancer24, 25.
Veiseh et al. in 201425 revealed a novel type of breast cancer phenotypic heterogeneity based on
the level of HA binding which was linked to pre-disposition to invade and metastasize. These
authors showed that binding levels of a fluorescent HA probe (F-HA) to human breast cancer
cell lines of different molecular subtypes (basal-like such as MDA-MB-231 and T4-2, and
luminal such as MCF-7 and SKBR3) were heterogeneous. The most malignant cell line, the
TNBC MDA-MB-231, exhibited the highest HA binding heterogeneity. Fluorescence-Activated
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Cell Sorting (FACS) identified MDA-MB-231 subpopulations that bind high levels of F-HA
(HAhigh) were unexpectedly different from those binding little or no probe (HAlow). HAhigh cells
proliferated slowly but were highly invasive in vitro and metastatic in vivo, while HAlow cells
were more proliferative but poorly invasive, and did not form detectable metastases. These
results are consistent with evidence linking high levels of HA to poor outcome of breast cancer
patients. Furthermore, elevated expression of HA receptors, which link HA to the cell surface
and mediate HA signaling instructions, have also been implicated in breast cancer aggression26.

Figure 1.3. Chemical structure of hyaluronan.
Repeating disaccharide unit of HA molecule consisting of D-glucuronic acid and N-acetylglucosamine,
linked with alternating β-1,4 and β-1,3 glycosidic bonds (Figure adapted from Bansal et al.27).
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1.2 Hyaluronan and Its Receptors
HA was isolated from the vitreous body of bovine eyes in 1934 by Meyer and Palmer28. Its
chemical structure, which consists of repeating disaccharide units of N‐acetylglucosamine
(GlcNAc) and D‐glucuronic acid (GlcUA) linked with alternating β‐1,4 and β‐1,3 glycosidic
bonds: [-β(1,4)-GlcUA-β(1,3)-GlcNAc-]n29 (Figure 1.3), was revealed 20 years later by
Weissmann et al.29. Under normal physiological conditions, HA can consist of up to 2,00025,000 disaccharides with a relative molecular mass of 1-10 MDa (each disaccharide is
approximately 400 daltons) and chain lengths of 2-25 μm (the average length of a disaccharide is
approximately 1 nm)30. The molecular mass of HA extracted from tissues ranges from 104-107
Da31,

32

. While HA is distributed in all tissues and body fluids of the human body, it is

abundantly expressed as a native homeostatic form in soft connective tissue and skin33.
At physiological pH, HA is highly negatively charged due to ionization of the carboxyl group of
the glucuronic acid34. The HA molecule is hydrophilic and based on its size can fold into
different conformations in water. Biophysical studies show that large HA (> 103 kDa) forms a
random coil, whereas very small (e.g., 10 kDa) HA form a rod high molecular weight HA35, 36.
Twists in the HA chain form hydrophobic patches, which allow interactions with cell
membranes, other HA chains, proteoglycans and other extracellular macromolecules that are
important in the organization of extracellular and pericellular matrices37. These hydrodynamic
characteristics of HA help to regulate the porosity and malleability of these matrices, which are
crucial factors in determining whether cells invade tissues during development, tissue
remodeling and cancer progression. In addition, a HA viscous meshwork protects cells against
mechanical forces and excludes large macromolecules; also, it slows the diffusion of substances
unable to penetrate the network38. In the body HA occurs in the salt form, hyaluronate, and
serves to lubricate, hydrate, or space-fill tissues such as joints and connective tissue39, 40. Besides
the viscoelastic and hydrating properties, HA has various signaling activity by binding to its
extracellular and intracellular binding proteins/receptors which will be discussed later. During
disease or tissue remodeling HA is degraded, as a result of free radicals or hyaluronidase
activity, into fragments that differ structurally and functionally from large HA41,

42

. Also,

different sizes of HA binds to different receptors and therefore the signaling outcome varies in
response to the size of HA bound36.
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1.2.1 Biology of Hyaluronan
The production of HA is a complex, tightly regulated, and multi-step process. HA is synthesized
by three distinct HA synthases that are found in vertebrates, certain bacteria, and chlorella virus
PBCV-143. The HA synthase genes in humans include three members: HAS1, HAS2, and HAS3.
The structures of the three genes are well-conserved with highly homologous amino
acid sequences, but the genes are located on separate chromosomes; HAS1 is located on
chromosome 19q13.4; HAS2 resides on chromosome 8q24.12; HAS3 is on chromosome
16q22.144. HAS1 gene has five exons, whereas HAS2 and HAS3 have four45. HAS1 and HAS3
have been shown to have splice variants. HAS1 has been shown to have splice variants in
Waldenström’s macroglobulinemia46, multiple myeloma47 and bladder cancer48. HAS3 has two
separate variant transcripts (4.9kb and 2.0kb) coding for proteins49. HASs are plasma membrane
proteins with seven transmembrane domains, two of which are located at the N-terminal end and
ﬁve at the C-terminal end (Figure 1.4 A) connected by a large cytoplasmic loop43,

50

. The

enzymes need Mg2+ or Mn2+ in addition to the two substrates UDP-glucuronic acid and UDP-Nacetylglucosamine. The expression of HAS isoforms is regulated in a different manner.
Transcriptional regulation of the three HAS genes varies with respect to developmental stage and
tissue type as well as in response to growth factors and cytokines. The three mammalian HAS
isoforms differ in kinetic characteristics and produced HA size. HAS2 synthesizes very large HA
molecules (> 2×103kDa), whereas smaller sizes of HA are synthesized by HAS1, and HAS3
(2×102-2×103 kDa)51.
The cellular synthesis of HA is a unique process; unlike most glycosaminoglycans, it is not made
in the cell’s Golgi network. Polymerization of HA takes place at the inner surface of the plasma
membrane52, and the growing HA chain may be extruded or translocated through the plasma
membrane, possibly through channels generated by oligomerization of HASs into the
extracellular space53, 54 (Figure 1.4 B).
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A

B

Figure 1.4. Schematic representation of mammalian HAS isoforms structure and a hypothetical
model for the HA synthesis.
(A) All mammalian HAS enzymes have seven membrane-spanning domains; two located at the Nterminal end and five at the C-terminal end. (B) The HAS enzymes use GlcNAc and GlcA from the
UDP-sugars to polymerize HA. They also transport the growing HA chains out of the cell through a
channel-like structure after polymerization at the inner surface of the plasma membrane (Figure
reproduced from Itano et al.51).
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1.2.2

Hyaluronan Receptors

HA was long considered to be an inert component acting only as “glue” or “space filler” for the
extracellular matrix. It is now established, however, that HA has many biological and instructive
functions55. Through its interactions with specific receptors, HA regulates several important
cellular processes such as proliferation, migration, differentiation, angiogenesis, and tumor
progression56. HA signaling properties are influenced by HA fragment size. For example, high
molecular weight HA has mediated antiangiogenic and immunosuppressive effects, whereas HA
fragments promote angiogenesis and inflammation57-60. HA fragmentation can occur as a result
of direct action of reactive oxygen and nitrogen species or hyaluronidase activity (e.g., Hyal1
and Hyal2)41,

42

. Furthermore, HA signaling properties is cell-specific depending on specific

receptor expression, specific signaling pathways, and cell cycle.
HA receptors bind HA via either a common domain called the link module, or a B(X7) B
consensus motif, where “B” represents arginine/lysine and “X” represents any non-acidic amino
acid61,

62

. The best-characterized HA receptors for functions in breast cancer are CD44 and

RHAMM (receptor for hyaluronic acid-mediated motility), which upon the binding to HA induce
the transduction of a range of intracellular signals, directly or by activating other receptors30.
HA can be tethered to the cell surface through interaction with receptors such as CD44 and
proteoglycan molecules, which are highly negatively charged and repel each another, causing
HA to extend out exhibit the cell surface in a brush-like configuration. As mentioned before, HA
can also be retained at the cell surface by sustained transmembrane interactions with its
synthases. HA retention can form a pericellular matrix/coat that as a protective barrier.
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1.2.2.1

Biology of CD44

CD44, the primary cell surface receptor for HA63, is a single pass transmembrane
glycoprotein, also referred to as P-glycoprotein 164. In human, it is encoded by a single gene
located on chromosome 11p1365, 66. The CD44 molecule consists of the extracellular domain
(ectodomain), the transmembrane domain, and the intracellular domain (cytoplasmic tail)66. This
glycoprotein was first discovered as a homing receptor for lymphocytes67,

68

called CD44H,

which is also known as the standard isoform (CD44s) as it is the simplest variant. CD44 is
subjected to alternative splicing. The CD44s, with a molecular weight of 85-90 kDa in SDS‐
PAGE, is the smallest form of CD44 and is expressed in most cell types69. Alternative splicing
happens at specific sites within the extracellular domain generating more than 20 isoforms with a
molecular weight of 85-200 kDa70-72. CD44s is encoded by nine non-variable exons, exons 1-5
and 16-20, while the variants of the receptor also include variable exons 6 to 15 (alternatively
designated v2- 10, exon v1 is not expressed in the human being)72-74 (Figure 1.5).
The extracellular region of CD44 can be divided into a distant conserved region, (with 85%
sequence identity between mammals) and a non-conserved region proximal to the plasma
membrane. The conserved region comprises N-glycosylation sites and the HA-binding link
module, while the non-conserved region contains sites for alternative splicing, O-glycosylation
with or without the addition of chondroitin sulphate or heparan sulphate75. Depending on cell
type and state of the cell, CD44 undergoes different posttranscriptional modifications such as
phosphorylation76, palmitoylation77, and proteolytic cleavage78, 79 or oligomerization80. CD44s is
widely expressed in a variety of normal tissues including all cell types of blood, lung, and
epidermis, whereas CD44 variants are expressed on a tissue- and differentiation-specific
manner71, 81.

14

Figure 1.5. Schematic representation of mouse CD44 gene/protein structures.
(A) The CD44 gene is comprised of 10 constant exons (exons 1–5 and 15–19) shown in tan that encode
the extracellular, transmembrane, cytoplasmic tail domains, and 10 variable exons- 9 variable exons in
human- for the extracellular domain (shown in silver). The exon 5a or exon v1 is not expressed in
humans. (B) Protein structures of the standard (CD44s) and variant CD44 (CD44v) proteins. Alternative
splicing of CD44 predominantly involves variable insertion of 10 extra exons (v1-v10) between exons 5
and 15. CD44v contains amino acid sequences between those encoded by exons 5 and 15 (exons 5a–14)
The relative sizes of the exons and introns are not drawn to scale ( Figure adapted from Inoue et al.82).

1.2.2.2

Biology of RHAMM

RHAMM, (receptor for hyaluronic acid-mediated motility), was first isolated and cloned from
subconfluent migrating cardiac fibroblasts as a cell surface HA receptor involved in cell
locomotion, but lacking a signal peptide for export through the Golgi ER83,

84

.

Although RHAMM was first located at the cell surface, it was also later discovered to also occur
as an intracellular protein, within the cytoplasm and in the nucleus85-88. The cell surface form of
RHAMM is designated as CD16889. The HMMR (Hyaluronan-Mediated Motility Receptor) gene
that encodes for RHAMM is located on chromosome 5q33.2 in humans and four different
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isoforms, generated by alternative splicing of its messenger RNA, are found both on cell surfaces
and inside the cells90,

91

. The constitutively expressed and most common RHAMM mRNA

transcript encodes the largest intracellular RHAMM protein, 85 kDa in human, that has been
designated as v592. Full-length RHAMM is encoded by 18 exons, and three variant forms are
encoded by alternatively spliced exon 4, 5, or 13 (Figure 1.6)93, 94. Full-length RHAMM and its
isoforms do not have the link module domain and GPI tail to integrate into the cell membrane90.
At the cell surface, RHAMM binds to HA and a number of receptor tyrosine kinases (RTKs) and
non-TK receptors, including PGFR91, TGFβ receptor-195, CD4496, 97, CD44-EGFR (epidermal
growth factor receptor ) complexes98, 99, bFGFR100, and RON101. All RHAMM isoforms have
two

positively

charged

B(X)7B motifs on its carboxyl terminal

that

are

required for HA binding62. TGFβ-1, RON, and the YAP-HIPPO pathway promote RHAMM
expression, while p53 and BRCA1 suppress its expression89,

95, 101-108

. Under the homeostatic

condition, RHAMM expression is tightly regulated and is absent or only present at low
concentrations. However, RHAMM mRNA and protein expression are transiently increased in
response to injury and during inflammation and cancer109.

Figure 1.6. Schematic representation of mouse RHAMM gene/protein structures.
The RHAMM gene is comprised of 18 exons. Full-length RHAMM encodes a 794-amino acid protein
sequence (85kDa protein with a 725-amino acid sequence in human). It contains two tubulin-binding
sites, at the N-terminus and C-terminus (exons 4 and 16), for binding to interphase and mitotic spindle
microtubules, respectively. Three isoforms are generated by alternative splicing of exon 4, 5, or 13. The
C-terminal of RHAMM contains HA and ERK binding sites. The relative sizes of the exons and introns
are not drawn to scale (Figure adapted from Misra et al.110).
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1.3 Hyaluronan, CD44, and RHAMM Crosstalk in TNBC
HA plays complex roles in TNBC, some of which result from its physicochemical properties and
some of which depend upon receptor mediated signaling110-112. The former is mechanical,
relating to purely physical interactions regulating cell-cell adhesion, cell migration, growth, and
differentiation. Furthermore, HA can physically protect cells against immune attack, and small
molecule therapeutics by forming pericellular coats30, 113-115. The latter is biological in nature,
involving the interaction of HA with its cell membrane receptors to induce signaling pathways
and subsequent genes’ expression. HA induces several signaling pathways upon binding to its
receptors. Both CD44 and RHAMM, which are known to have roles in cancer pathogenesis,
mediate HA signaling90. While CD44 and RHAMM can interact independently with HA, in
some cases, they exhibit both cooperative and interchangeable functions. For example,
interactions at the cell surface between CD44 and RHAMM have been shown to activate
signaling cascades which promote cancer cell motility89. Sometimes, RHAMM can compensate
for loss of CD44 in binding HA, which should be considered in experiments with CD44-null
mice116.
As has been mentioned earlier, all CD44 isoforms contain a link module HA-binding site in their
extracellular domain. When HA binds to CD44, it brings CD44 in close proximity to signaling
receptors such as ErbB2, EGFR, or TGF-β type 1 receptors, allowing for direct association and
interaction between receptors and their signaling complexes in a tightly localized lipid raft 117. In
response to HA binding, and depending on the cellular context, the intracellular domain of CD44
variants selectively interacts with many regulatory and adaptor proteins and modulates specific
signaling pathways118,

119

. Therefore, the binding of CD44 to HA affects cell adhesion to

extracellular matrix components and is also involved in the stimulation of aggregation,
proliferation, migration, and angiogenesis119-122.
Mitogen-activated protein kinase (MAPK) cascades are the major signal transducing pathways
that are activated by HA: HA receptor interactions. Activation of upstream molecules such as
EGFR stimulates the activation of downstream MAPK kinases that are involved in a variety of
fundamental cellular processes such as proliferation, differentiation, motility, stress response,
apoptosis, and survival. Each kinase phosphorylates and, thereby, activates the next member in

17

sequence. The most relevant of all, for intracellular mechanisms involved in TNBC, are the
activated extracellular signal-regulated kinase/mitogen-activated protein kinase (ERK/MAPK),
c-Jun N-Terminal Kinase/c-Jun (JNK/c-Jun), as well as the phosphoinositol-3-kinase/ Protein
kinase B (PI3K/Akt) pathways118,

119

. ERK is one of the proteins that is phosphorylated on

tyrosine as a result of HA/RHAMM interactions123.
HA and its receptors CD44 and RHAMM have been implicated in all steps of breast cancer
progression such as migration, invasion, adhesion, and proliferation. In this thesis, emphasis is
placed upon their contribution to cell proliferation and drug resistance.

1.3.1 Hyaluronan, CD44, and RHAMM in Tumorigenesis
HA, and its receptors CD44 and RHAMM, contribute to tumorigenesis through their effects on
cell proliferation. Some of these effects are the result of the physical properties of HA and some
are mediated by binding of HA to CD44 and RHAMM and the subsequebt activation of cellular
proliferation124, 125.
HA facilitates cancer cell proliferation by the formation of highly hydrated matrices that
facilitate enhanced cell proliferation124. Increased HA synthesis in cancer cells results in the
formation of hydrated and less dense matrix that facilitate tumor cell motility and invasion126.
However, HA has a dual effect on cell proliferation; high molecular weight HA (HMW-HA) has
a protective effect against cancer cell proliferation and tumorigenesis. For example, HMW-HA
treatment has been shown to inhibit growth in a human colon carcinoma xenograft after
chemotherapy127. On the other hand, LMW-HA promotes progression of breast cancer (MDAMB-231 cells)128.
Furthermore, HA can promote proliferation by activating several signaling cascades in cancer
cells. HA promotes the interaction of CD44 and EGFR resulting in activation of MAPK pathway
and further induction of cell proliferation124.
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The functional roles of CD44 and RHAMM in tumorigenesis are largely a consequence of their
ability to bind HA and activate signaling pathways that are implicated in breast cancer
progression. CD44 has dual functions in both tumor cell proliferation and growth inhibition,
dependent on biological conditions. CD44 promotes or inhibits cell proliferation when cells are
at low density or confluent, respectively. Also, the dual functions of CD44 in cancer depend on
expression of specific variant isoforms of CD44v, which regulate tumor-initiating cells in
subpopulations of cancer cells129. Expression of distinct variants of CD44 is linked with
progression and metastasis of cancer cells as well as patient prognosis130, 131. Similarly, RHAMM
has dual functions to maintain cell behavior. Overexpression of RHAMM was found in highly
proliferative cells in breast cancer and multiple myeloma132, whereas loss of RHAMM is linked
to peripheral nerve sheath tumor progression133.
Several studies have addressed RHAMM contribution to cell proliferation98, 134, 135. Mohapatra et
al.134 showed that interfering with RHAMM functions, either by using soluble recombinant
RHAMM protein or by suppressing its function by using dominant negative mutant or antisense
RHAMM, results in decreased levels of Cdc2 and Cyclin B1 proteins and consequently a G2/M
arrest in H-ras transformed fibroblasts. Soluble RHAMM causes G2/M arrest in ras-transformed
fibroblasts without affecting their progression through S-phase135. Moreover, it has been shown
that RHAMM induces proliferative activities of cementifying fibroma cells through a mechanism
that involves the interaction of CD44 and EGFR90.

1.3.2 Hyaluronan, CD44, RHAMM, and Regulation of Multidrug Resistance
Drug resistance in tumor cells can arise in numerous ways, such as through decreased access to
or uptake of anti-cancer drugs, increased anti-cancer drug efflux, and activation of repair and
detoxifying systems30. Classic multidrug resistance generally results from elevated drug export
through the ATP-dependent efflux pumps, such as MDR (multidrug resistance), MRP
(multidrug-resistance protein) and other members of the ATP-binding cassette (ABC) transporter
families136. Moreover, it is known that alterations in cell survival and apoptotic signalling
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pathways are related to drug resistance in cancer cells22. Therefore, therapeutic interventions that
induce downstream events in the apoptotic cascade might help to overcome drug resistance in
patients137, 138.
HA and its receptors are involved in promotion and regulation of multidrug resistance in a
variety of cancer cell types via both receptor-dependent and/or -independent pathways139, 140

141

.

First, HA can bind to its cell surface receptors such as CD44 and RHAMM to form a coat of HA
on cancer cells. This pericellular HA coat promotes drug resistance by preventing/decreasing the
uptake of cytotoxic drugs. Results of clinical studies have demonstrated the enhanced efficacy of
chemotherapeutic agents in cancer patients pretreated with bovine hyaluronidase142.
Furthermore, the interaction of HA and CD44 in cancer cells has been strongly implicated in the
development of drug resistance139, 140. It has been reported that HA: CD44 interactions promote
expression of multidrug transporter1 (MDR1)143, P-glycoprotein, and multidrug resistance
protein 2 (MRP2), stimulating chemoresistance in breast cancer cells141. Slomiany et al.144, 145
showed that treatment of cells with HA oligosaccharides induces rapid internalization of the drug
transporters, BCRP and P-glycoprotein. They concluded that the effect of HA on transporter
expression may be mediated by stabilization of these transporters in the plasma membrane rather
than on synthesis. HA can be tethered to its receptors such as CD44 and RHAMM at the plasma
membrane and stabilizes actin-linked CD44-transporter complexes in lipid microdomains
(Figure 1.7).
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Figure 1.7. HA: CD44 interaction stabilize multidrug transporters in the plasma membrane.
HA is synthesized by HAS2 and binds to CD44 at the plasma membrane whereby it stabilizes CD44transporter complexes in lipid microdomains. The interaction between CD44 and multidrug transporters is
not direct and the orange oval depicts unidentified proteins (Figure reproduced from Toole et al.146).

Finally, HA and its receptors alter drug resistance by stimulating cell-survival signalling
pathways (Figure 1.8). Increased HA production was found to stimulate drug resistance in drugsensitive cancer cells. In addition, disruption of endogenous HA-induced signaling suppresses
drug resistance in several cancer cell lines, including TNBC MDA-MB-23122. HA: CD44
interactions promote resistance to a variety of chemotherapeutic drugs, by activation of PI3K
signaling that supports cell survival via AKT and induces multidrug transporter22,

143

. PI3K

signaling modulates multidrug resistance (MDR) transporter expression and function and
phosphorylates Akt (p-Akt) to activate cell-survival signaling. Moreover, the HA: CD44
interaction induces c-Jun signaling pathway which plays a crucial role in oncogenic microRNA21 production resulting in survival protein (Bcl-2/IAP) and MDR1 upregulation and
consequently chemoresistance in TNBC118. MicroRNAs (miRNAs) (of about 21–25 nucleotides)
are single-stranded RNAs that are involved in the modulation of gene expression at the
posttranslational level. Furthermore, HA: CD44: RHAMM multidrug resistance can be promoted
through the mammalian Hippo signaling pathway. Upon binding HA to CD44, the HIPPO
pathway becomes blocked, which results in increased apoptosis resistance147, 148. In a feedback
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loop, activated YAP, one of the Hippo pathway component, binds to the promoter of RHAMM,
thereby inducing RHAMM transcription149, 150.
Although RHAMM can be involved in CD44/HA effect in chemoresistance, to my knowledge,
no study has yet investigated the direct role of RHAMM in multidrug resistance.

Figure 1.8. HA, CD44, RHAMM and regulation of drug resistance.
HA/CD44/ RHAMM complex activates a couple of signaling pathways that lead to increased cell survival
and multidrug resistance.
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1.4 The Raf/MEK/ERK Pathway as a Drug Target in TNBC
Interactions between HA and its receptors, CD44 and RHAMM, result in a ligand-clustering and
activation of several signaling pathways including the Raf/MEK/ERK pathway. Both CD44 and
cell-surface RHAMM function as co-receptors to activate receptor tyrosine kinases (RTKs) such
as EGFR, c-MET, and PDGFR. Intracellular RHAMM forms complexes with approximately
20% of total cellular MEK1:ERK1/2 kinases91, as determined by co-immunoprecipitation
analyses (Figure 1.9). RHAMM contains recognition sequences for ERK1/2 and direct binding
and site-directed mutation assays show that intracellular RHAMM binds directly to ERK1 but
only indirectly with ERK2 and MEK1. RHAMM’s function in ERK1/2:MEK1 complexes
appears to be as a scaffold protein that directs these complexes to subcellular compartments (e.g.,
nucleus, membrane extensions) and affects the kinetics of ERK1/2 activation.
The Raf/MEK/ERK is a kinase cascade whose targets are cytoskeletal proteins and transcription
factors (Figure 1.9). Upon ligand activation of growth factor receptors, Ras associates with GTP
and activates Raf (Raf-1, B-Raf and A-Raf) which phosphorylates the upstream kinase activator
of ERK1/2 (i.e., mitogen-associated/extracellular regulated kinase-1 [MEK1]). MEK1 activates
extracellular signal-regulated kinases 1 and 2 (ERK1 and ERK2) on specific threonine and
tyrosine residues (at Thr202/Tyr204 for human ERK1 and Thr185/Tyr187 for human ERK2).
ERK1/2 are highly related proteins that knockout experiments show can perform different
functions151. When expressed together, ERK1/2 either phosphorylate and activate a variety of
substrates in the cytoplasm including transcription factors that then translocate into the nucleus,
or themselves translocate into the nucleus where they directly participate in transcriptional
complexes152, particularly those regulating genes that are involved in apoptosis and cytotoxic
drug resistance.
The ability of the Raf/MEK/ERK pathway to promote expression of genes involved in apoptosis
and cytotoxic drug resistance promotes cell survival during therapy. For example, this pathway
phosphorylates apoptotic regulatory machinery including Bcl-2, Bad, Bim, Mcl-1, and caspase
9152, 153. Furthermore, increased expression of Raf increases the levels of both the MDR1 drug
pump and the anti-apoptotic Bcl-2 protein in MCF-7 breast cancer cells154, 155, which has been
associated with drug resistance in these cells.
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The Raf/MEK/ERK kinase cascade also regulates breast cancer cell motility, necessary for
invasion and metastasis156, 157. Invasive/highly motile breast cancer cell lines such as MDA-MB231 utilize cell surface RHAMM and CD44 to coordinate an HA-dependent autocrine
mechanism that sustains ERK1/2 signaling leading to cell motility156. Therefore, Raf/MEK/ERK
signaling is key to breast cancer progression as it contributes to cytotoxic drug resistance and
increased motility and invasion in MDA-MB-231 cells.
A large body of clinical observations validates the important role of the Raf/MEK/ERK in breast
cancer. The pathway is deregulated in approximately a third of human cancers, particularly those
of epithelial origin. The pathway is associated with breast cancer progression as the increased
ERK1/2 activity is linked to shorter disease-free survival, and is prognostic for recurrence-free
survival in patients with breast cancer158, 159. Elevated levels of active ERK/MAPK have been
shown to be a marker of breast cancer metastasis and predict metastasis to the lymph nodes160.
This association is particularly apparent in TNBC. In TNBC, the MAPK pathway is more
commonly activated161, 162 particularly in metastatic sites when compared to other breast cancer
subtypes160, 163. Eralp et al.162 showed that a higher level of MAPK expression is associated with
shorter disease-free survival and increased anthracycline resistance in patients with TNBC
tumors. Bartholomeusz et al.159 reported that TNBC patients with ERK2-overexpressing tumors
have a higher risk of death than those with low ERK2-expressing tumors.
Given the wealth of preclinical data and clinical observations regarding the Raf/MEK/ERK
pathway in cell survival and cytotoxic drug resistance, triggering this pathway would be a
reasonable

approach

chemotherapeutic drugs.

to

eradicate

invasive

tumor

cells

that

are

resistant

to
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Figure 1.9. Schematic overview of the Raf/MEK/ERK signaling pathway upon binding HA to
CD44 and RHAMM.
External stimuli, including binding HA to CD44 and RHAMM, initiate the activation of Ras, a small
GTPase, through membrane-associated signaling complexes. Ras facilitates the heterodimerization and
activation of Raf intracellular kinases, which starts a kinase cascade through MEK and ERK. This
results in the activation of transcription factors that drive genomic signature programs of dysregulated
cell cycle progression, proliferation, survival, migration, invasion.
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1.5 Hypothesis and Objectives
Since elevated HA production/binding and low cell proliferation rate are linked to
chemoresistance, I hypothesized that the HAhigh subset is more resistant to chemotherapy than the
HAlow subset and serves as a model for targeted therapy.

The objectives for this dissertation were as follows:
1. To compare sensitivity of HAhigh and HAlow tumor cell subpopulations to chemotherapy
in vitro
2. To compare sensitivity of HAhigh and HAlow tumor cell subpopulations to targeted therapy
in vitro

I used the MDA-MB-231 cell line, which models TNBC and exhibits a high degree of HA
binding heterogeneity25, to assess response to chemotherapy (doxorubicin) and to identify
potential targeted therapies. MDA-MB-231 was originally isolated from the pleural effusion of a
Caucasian breast adenocarcinoma patient. It belongs to the Claudin-low intrinsic subtype which
is characterized by the low expression of tight-junctions related genes (E- cadherin, claudin-3, -4,
and 7) and high expression of mesenchymal and stem-like biological processes (CD44/CD24
mRNA Ratio: 1.37, and CD49f/EpCAM mRNA Ratio: 1.17)164, 165. MDA-MB-231 cells harbour
K-Ras, H-Ras and BRAF mutations.
Doxorubicin (trade name: Adriamycin PFS), an anthracycline antibiotic, is the most widely used
agent in the treatment of (TNBC) breast cancer, both as a single agent as well as in combination
with other drugs. Also, it is considered the most active single agent in breast cancer.
Doxorubicin’s mechanism of anticancer action is not well understood. It is proposed that
doxorubicin slows or blocks cell proliferation by intercalating into DNA helix and disrupting
topoisomerase II and consequently inhibiting DNA replication and repair. Doxorubicin also is
capable of increasing generation of free radicals leading to DNA and cell membrane damage
(Figure 1.10). Intercalating into DNA and producing of free radicals are unlikely to be clinically
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relevant as the concentration of doxorubicin required to produce these effects is much higher
than that achievable in patients (1.4 to 34.4 µmol/L)166-168. Inhibition of topoisomerase II by
doxorubicin at clinically achievable concentrations causes DNA breaks168.

Figure 1.10. A proposed model for doxorubicin’s mechanisms of anti-cancer.
Doxorubicin exerts its cytotoxicity through several different mechanisms. It inhibits topoisomerase II
(TOP2A) by intercalating into DNA. Also, it causes the formation of free radicals that leads to the cell
membrane and/or DNA damage followed by cell death.
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Chapter 2

2

« Materials and Methods »

2.1 Cell Culture
Human breast cancer MDA-MB-231 cell line was purchased from American Type Culture
Collection (ATCC; Manassas, USA). RHAMM-/- MDA-MB-231 cells generated by
CRISPR/Cas9 gene editing system were obtained from Dr. James B. McCarthy (University of
Minnesota, Minneapolis, MN). Cell lines were grown on 75 cm2 or 175 cm2 tissue culture plastic
flasks (Sarstedt Inc.) in low glucose (1.0 g/L) Dulbecco’s Modified Eagle Medium (DMEM)
(Wisent BioProducts, St. Burno, Quebec, Canada) supplemented with 10% (v/v) Fetal Bovine
Serum (FBS) (Wisent BioProducts) and 50 µg/mL Gibco™ Penicillin-Streptomycin (Invitrogen,
Life Technologies, Burlington, ON, Canada) in a 37˚C humidified atmosphere of 5% CO2. Cells
were passaged every 3 days at 80% confluence using 0.25% trypsin-0.5 mM EDTA (Wisent
BioProducts).

2.2 Fluorescence-Activated Cell Sorting
Fluorescent HA (F-HA) probe was synthesized following established procedures (Veiseh et al.
2014)25. Briefly, 200 µL of polydisperse 132 kDa Sodium Hyaluronate (1%, Lifecore) were
added to 300 µL Alexa fluor 647 hydrazide dye (1 mg/mL, Life Technologies) in 1 mL of
conjugation buffer (20 mM MES, 30% EtOH, 0.0028 g/mL 1-Ethyl-3-(3-dimethylaminopropyl)
carbodiimide. After overnight incubation of the mixture at room temperature (20-27˚C),
unconjugated dye was removed by dialyzing the mixture in 3 mL slide-a-lyzer cassettes (10,000
MWCO, Thermoscientific) against 1X PBS (10 mM PO43−, 137 mM NaCl, and 2.7 mM KCl)
four times using 2 liters per dialysis for 24 hours for each dialysis. In preparation for
Fluorescence-Activated Cell Sorting (FACS), 50-60% confluent MDA-MB-231 cells were
detached from tissue culture flasks with 2 mM EDTA, centrifuged at 1,200 rpm for 3 minutes
and suspended at 1×106 cells in 1 mL PBS followed by incubation with 133 μg/mL F-HA for 45
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minutes in the dark on ice. After 3X washes with PBS, cells were suspended at a concentration
of 10×106 cells/mL for sorting using a BD FACSariaTM III flow cytometry machine (BD
Biosciences, Franklin Lakes, NJ). Cells were sorted to HAlow and HAhigh based on the fluorescent
intensity (5-8% of minimum and maximum signal selection). The HAlow gate was set based on
the corresponding unstained control sample. The HAhigh gate was set on the upper shoulder of the
stained cell population and was verified to be a discrete cell cluster separated from the main cell
population. To determine the post-sort purity of HAhigh and HAlowcells, 200 events were recorded
from each isolated cell populations back on the sorter.

2.3 Cell Surface Marker and ALDH Activity Analyses
To compare the proportion of stem-like (ALDHhighCD44+) and non-stem-like (ALDHlowCD44-)
cell populations in HAhigh and HAlow subpopulations, ALDH activity and cell surface expression
of CD44 and CD24 were assessed. The ALDEFLUOR® assay kit (StemCell Technologies,
Vancouver, BC) was used to isolate the population with a high ALDH enzymatic activity. The
basis for this assay is that uncharged ALDH substrate (BODIPY-aminoacetaldehyde [BAAA]) is
taken up by living cells via passive diffusion. Once inside the cell, BAAA is converted into
negatively-charged BODIPY-aminoacetate (BAA) by intracellular ALDH. BAA-is retained
inside the cell, causing the cell to become highly fluorescent. Only cells with an intact cell
membrane can retain BAA-, so only viable cells can be identified. The ALDEFLUOR® assay
was performed essentially as described by Ginestier et al169.
MDA-MB-231 cells at 50% confluency in DMEM+10% FBS were released from the tissue
culture surface using 2 mM EDTA. After 2X washing with 1X PBS, cells were suspended in
ALDEFLUOR® assay buffer containing ALDH substrate (BAAA, 1×106 cells/mL), and
incubated for 45 minutes at 37˚ C to allow substrate conversion. As a negative control, an aliquot
was treated with 50 mmol/l diethylaminobenzaldehyde (DEAB), a speciﬁc ALDH inhibitor. To
compare the expression of cell surface CD44 and CD24 in HAhigh and HAlow subpopulations,
1×106 cells/mL assay buffer were incubated with CD24-PE antibody (clone ML5; BD
Biosciences Canada, Mississauga, ON) (1:1000), together with CD44-PE/Cy7 antibody (1:1000)
(Clone IM7.8.1, Life Technologies) and Alexa Fluor 647-HA (133 µg/mL) for 30 minutes in the
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dark on ice. Finally, cells were washed three times with 1 mL 1X PBS before flow cytometry
analyses. Cell ﬂuorescence intensity was determined using a FACS Calibur II flow cytometer
and the CellquestTM Pro software (BD Biosciences, Franklin Lakes, NJ). Flow data were
analyzed using FlowJo® V10 software (Tree Star, Inc., Ashland, OR, USA). I considered ALDH
activity as the primary sort criteria and CD44+CD24- phenotype as the secondary sort criteria.

2.4 Half Maximal Inhibitory Concentration Assays
To determine the half maximal inhibitory concentration of doxorubicin, and MEK inhibitors
PD98059 and trametinib, cells (96K cells/96 well plates) were plated and 24 hours later exposed
to a single dose of agents for 72 hours. Metabolically viable cells were quantified using
alamarBlue® as per the manufacturer’s instructions (Invitrogen, Life Technologies). Briefly,
1/10th volume of alamarBlue reagent was added to wells and incubated for 4 hours at 37°C in a
cell culture incubator. The fluorescent signal intensity which is directly proportional to cell
number was measured at 590 nm on the Wallac 1420 VICTOR 2 plate reader (Perkin-Elmer,
Waltham, MA). Finally, results are analyzed by plotting fluorescence intensity versus
compounds concentration.

2.5 Intracellular Doxorubicin Accumulation
To assess the intracellular accumulation of doxorubicin, HAhigh and HAlow cells were plated on
coverslips coated with 5% fibronectin at approximately 50% confluence (48K cells/24 well
plates). After 24 hours, cells were incubated with 0.5 µM doxorubicin for 2 hours, as literaturereported doxorubicin accumulation in nuclei and cytoplasm of MDA-MB-435 cells was highest
at 2 hours170, at 37°C. Then the cells were washed twice with ice-cold PBS. Coverslips were
mounted with 40 µL ProLong® Gold Antifade Mountant with DAPI (Molecular probes, Life
Technologies) and images were captured using an Olympus Confocal microscope and
FluoView™ FV1000 software. Doxorubicin fluorescence was excited at 488 nm, and the
emission was collected through a 530 nm long-pass filter. Cell images (>40 per group) were
analyzed as mean intracellular doxorubicin fluorescent intensity using ImageJ software (NIH,
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Bethesda, MD). To compare intracellular accumulation of doxorubicin in HAhigh and HAlow cells
by flow cytometry, 50-60 subconfluent cells were incubated with 0.5 µM doxorubicin for 2
hours at 37°C. Then, cells were released from tissue culture surface using 2 mM EDTA and
washed 2X ice-cold PBS before analysis by flow cytometry.

2.6 HA Synthase 2 Immunofluorescence Staining
Cells were plated on coverslips coated with 5% fibronectin at approximately 50% confluence
(48K cells/24 well plates). On the following day, cells were fixed (1 mL 3.7%
paraformaldehyde/coverslip for 10 minutes at room temperature (20-27˚C)), permeabilized (1
mL 1% BSA/0.3% Triton X-100 in TBS for 15 minutes at room temperature (20-27˚C)), and
blocked overnight at 4˚C (1 mL 5% FBS in TBS/coverslip). Then cells were incubated with 200
µL HAS2 (S-15) antibody (sc-34067) from Santa Cruz (Dallas, USA) for 1 hour at room
temperature (20-27˚C) followed by 3X washes with PBS/1% BSA and incubation with Alexa
Fluor 488 secondary antibody (ab150129) for 1 hour at room temperature (20-27˚C) on rocker
(400 rpm). After 4X washing, coverslips were mounted with 40 µL ProLong® Gold Antifade
Mountant with DAPI per coverslip (Molecular Probes, Life Technologies) and fluorescent
images were collected using an Olympus Confocal microscope and FluoView™ FV1000
software. Cell images (>40 per group) were analyzed as mean fluorescent intensity using ImageJ
software (NIH, Bethesda, MD).

2.7 HA Production
To measure the amount of HA secretion, tissue culture supernatants were collected from 50-60%
subconfluent cultures after 48 hours culture, and metabolically viable cells were quantified using
alamarBlue for normalization. HA concentration in supernatants was quantified by a sandwich
ELISA kit (K-4800, Echelon Biosciences Inc., Salt Lake City, UT) per the manufacture’s
protocol. Briefly, HAhigh and HAlow cell culture supernatants and standards (100 μL) were
incubated in ELISA wells for 1 hour at room temperature (20-27˚C). After 3X washing with 200
µL/well 1X TBS buffer (50 mM Tris-Cl, pH 7.6, 150 mM NaCl), wells were incubated with 100
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µL of HA detector solution for 1 hour at room temperature (20-27˚C). Then, wells were washed
3X 200 µL/well 1X TBS buffer followed by incubation with 100 µL TMB solution/well (KTMB1; for approximately 20-30 minutes until blue color develops. Finally, 50 µL of 1N H2SO4
solution was added to each well and after tapping plate to mix, OD was recorded at 450 nm and
HA concentrations were determined by interpolating relative sample OD values to the standard
curve. The kit measures HA larger than 10 disaccharides (4500 Da).

2.8 Flow Cytometry Assays of F-HA Binding and Cell Surface
RHAMM and CD44 Expression
To compare the expression of cell surface RHAMM and CD44 in HAhigh and HAlow
subpopulations, cells at 50% confluency in DMEM supplemented with 10% FBS were released
from the tissue culture surface using 2 mM EDTA. After further washing, 1×106 cells/1 mL PBS
were incubated with 1:20 monoclonal mouse anti-RHAMM (6B7B7) for 30 minutes on ice. Cells
were washed twice with 1 mL 1X PBS and were incubated with Rat anti-mouse Alexa Fluor 488
(1:2000) secondary antibody, together with Rabbit anti-mouse CD44-RPE conjugate (1:1000)
(Clone IM7.8.1, Life Technologies) and Alexa Fluor 647-HA (133 µg/mL) for 30 minutes in the
dark on ice. Finally, cells were washed three times with 1 mL 1X PBS before flow cytometry
analyses. Cell ﬂuorescence intensity was determined using a FACSCalibur IITM flow cytometer
and the CellquestTM Pro software (BD Biosciences, Franklin Lakes, NJ). Flow data were
analyzed using FlowJo® V10 software (Tree Star, Inc., Ashland, OR, USA).

2.9 Analysis of RNA Expression Levels
Total RNA was extracted using TRIzol Reagent (Invitrogen, Life Technologies) as per the
manufacturer’s instructions. Briefly, after removing growth media, cells were washed with cold
PBS and directly lysed in the culture dish by addition of 1 mL TRIzol/10 cm2. After passing the
cell lysate through a pipette several times, chloroform was added (1/5 of the volume of TRIzol
used) and the lysate was mixed. The RNA-containing aqueous phase was recovered after
centrifuging for 15 minutes at 12,000×g. The aqueous phase was mixed with 100% isopropanol
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(1/2 of the volume of TRIzol used), incubation for 10 minutes at room temperature (20-27˚C)
and centrifuged at 12,000×g for 10 minutes. The pellet was washed with 75% ethanol (the equal
volume of TRIzol used), air dried, and resuspended in RNase-free water (20-50 µL). RNA
quantity and quality were determined by absorbance at 260 nm and 260/280 nm using an ND1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE). Absorbance ratios of 1.8–
2.0 were considered of acceptable purity. RNA samples were sent to the London Regional
Genomics Centre (Robarts Research Institute, London, Ontario, Canada) for expression
profiling. RNA quality was reassessed using the Agilent 2100 Bioanalyzer (Agilent
Technologies Inc., Palo Alto, CA) and the RNA 6000 Nano kit (Caliper Life Sciences, Mountain
View, CA). Single-stranded complementary DNA was prepared from 200 ng of total RNA as per
the Ambion WT Expression Kit for Affymetrix GeneChip Whole Transcript WT Expression
Arrays (Applied Biosystems, Carlsbad, CA) and the Affymetrix GeneChip WT Terminal
Labeling kit and Hybridization User Manual171 (Affymetrix, Santa Clara, CA). Total RNA was
first converted to cDNA, followed by in vitro transcription to make cRNA. Single-stranded
cDNA (5.5 ug) was synthesized; end labelled and hybridized, for 16 hours at 45°C, to Human
Gene 2.0 ST arrays. All liquid handling steps were performed by a GeneChip Fluidics Station
450 and GeneChips were scanned and images were captured using the GeneChip Scanner 3000
7G (Affymetrix, Santa Clara, CA) using Command Console v3.2.4. Probe level (.CEL file) data
were generated using Affymetrix Command Console v3.2.4. Probes were summarized to gene
level data in Partek Genomics Suite v6.6 (Partek, St. Louis, MO) using the RMA (Robust Multichip Average) algorithm172. Partek was used to determine gene level ANOVA p-values and fold
changes.

2.10 Quantitative Real-time RT-PCR
Quantitative Real-time RT-PCR was used to verify gene expression results obtained from mRNA
microarray analysis. cDNA was synthesized using Random Primers (Invitrogen, Life
Technologies) in a first strand cDNA synthesis reaction using Superscript TM II Reverse
Transcriptase (Invitrogen, Life Technologies) as per the manufacturer’s instructions. Briefly, a
mixture of 1 µg total RNA, 1 µL Oligo (dT) 12-18 (500 µg/mL), and 1 µL dNTP Mix (10 mM
each) was heated at 65°C for 5 minutes and cooled on ice for 5 min. After a brief centrifuge to
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collect the content of the tube, 4 µL of 5X First-Strand Buffer (250 mM Tris-HCl (pH 8.3 at
room temperature), 375 mM KCl, 15 mM MgCl2) and 2 µL of 0.1 M DTT (Dithiothreitol) were
added and incubated at 42°C for 2 minutes. Finally, 1 µL of SuperscriptTM II Reverse
Transcriptase was added and incubated at 42°C for 50 minutes followed by heating at 70°C for
15 minutes.
PCR reactions were performed using SYBR® Green QPCR Master Mix (Agilent Technologies,
Mississauga, ON, Canada) and a Stratagene Mx3000P instrument (Agilent Technologies).
Human-specific primers set used were F: 5´ TTGGGGGAGATGTCCAGA 3´ and R: 5´
CGCTTCGTAGGTCATCCAC 3´ for HAS2, and F: 5’-ACCCACTCCTCCACCTTTGA-3’ R:
5’-CTGTTGCTGTAGCCAAATTCGT-3’ for GAPDH (Thermo Fisher scientific, Burlington,
CA). The following cycle conditions were used: 3 minutes at 95°C, 20 seconds at 95°C, 20
seconds at 60°C, 1 minute at 95°C, 30 seconds at 60°C, and 30 seconds at 95°C. Relative
expression levels were calculated by the standard curve method and analyzed using Stratagene
Mx3000P software as well as Microsoft Excel. GAPDH served as an endogenous reference.

2.11 METABRIC analysis
Datasets from the METABRIC (Molecular Taxonomy of Breast Cancer International
Consortium) analysis of breast cancer samples were downloaded from the Memorial SloanKettering Cancer Center’s cbioPortal for Cancer Genomics (http://www.cbioportal.org/)173, 174.
Raw data were analyzed using the DNACopy package to generate gene-level copy-number
variation (CNV). METABRIC transcriptomics samples were generated using the Illumina
HumanHT-12 v3 platform (Illumina Human WG-v3) and the CNA using Affymetrix SNP 6.0.

2.12 ERK 1/2 Activity and Localization
Total ERK1/2 and phosphorylated ERK1/2 (Thr202/Tyr204) were determined using ELISA kit
(ab176660) as manufacturers’ instructions. Briefly, 50 µl of RHAMM-/- and RHAMM+/+ MDAMB-231 cell lysates and standards as well as 50µl of the Antibody Cocktail (affinity tag labelled
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capture antibody and a reporter conjugated detector antibody 1:1) were incubated in ELISA
wells for 1 hour at room temperature (20-27˚C) on a plate shaker set to 400 rpm. After 3X
washing with 350 µL/well 1X wash buffer, wells were incubated with 100 µL of TMB for 15
minutes in the dark on a plate shaker set to 400 rpm. Finally, 100 µL of stop solution was added
to each well and after 1 minute mixing on a plate shaker (400 rpm), OD was recorded at 450 nm.
Total ERK1/2 and phosphorylated ERK1/2 protein concentrations were determined based on
ODs. To determine the localization of activated ERK1/2, cells were plated on coverslips coated
with 5% fibronectin at approximately 50% confluence for immunofluorescence staining. On the
following day, cells were fixed (1 mL 3.7% paraformaldehyde/coverslip for 10 minutes at RT),
permeabilized (1 mL 1% BSA/0.3% Triton X-100 in TBS for 15 minutes at room temperature
(20-27˚C)), and blocked overnight at 4˚C (1 mL 5% FBS in TBS/coverslip). Then cells were
incubated with 200 µL Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (197G2) Rabbit mAb
for 1 hour at room temperature on rocker (400 rpm) followed by 4X 1 mL
TBS/1%BSA/coverslip washes. Then, coverslips were mounted with 40 µL ProLong® Gold
Antifade Mountant with DAPI per coverslip (Molecular Probes, Life Technologies) and
fluorescent images were collected using an Olympus Confocal microscope and FluoView™
FV1000 software. Cell images (>40 per group) were analyzed as mean fluorescent intensity
using ImageJ software (NIH, Bethesda, MD).

2.13 Generating RHAMM Knockout MDA-MB-231 Cell Line
The RHAMM-/- MDA-MB-231 cell line was generated by transfection with paired guide RNAs
(5’ GTATTGTATTTGATTAGAAT 3’, and 5’ GAATTTGAGAATTCTAAGCT 3’ in plasmid
pCR4-TOPO-U6-HPRT-gRNA), that bind in exons 3 and 6, respectively. Briefly, in a 6 well
plate, the gRNA1 (2 ug) and gRNA2 (2 ug) were co-transfected with the plasmid expressing the
CAS9 enzyme (pT3.5 Caggs-FLAG-hCas9) (2 ug) as well as two plasmids for puromycin and
GFP selection, pcDNA-PB7 (0.5 ug) and pPBSB-CG-LUC-GFP(Puro) (+CRE) (0.5 ug).
Transfection was performed using the UltraCruz® Transfection Reagent (sc-395739) from Santa
Cruz Biotechnology as per the manufacturer’s instructions. Cells were plated clonally in 96 well
plates 48 hours post-transfection in the presence of 0.6 ug/mL puromycin. Clones were screened
initially by genomic PCR to detect clones harboring the genomic deletion using the Platinum™
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DNA

Polymerase

system

5’AGATACTACCTTGCCTGCTTCA3’

(Invitrogen)
and

with

the

following

primers:

5’ACCTGCAGCTTCATCTCCAT3’.

Subsequently, clones with the genomic deletion were also screened by western blot.
RHAMM-/- MDA-MB-231 cell line was generated by the laboratory of Dr. James B. McCarthy
(University of Minnesota, Minneapolis, MN). The guide RNAs were designed and the plasmids
constructed by the laboratory of Dr. Brandon Moriarity (University of Minnesota, Minneapolis,
MN). All additional plasmids listed for CAS9 expression and CRISPR selection were kindly
provided by Dr. Brandon Moriarity.

2.14 Statistical Analysis
Data were expressed as mean ± SEM. Statistical differences between two means were assessed
using a two-tailed Student t-test with significance set at p< 0.05 as indicated. Statistical
differences between survival curves of two groups were assessed using a log-rank test with
significance set at p< 0.05 as indicated.
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Chapter 3

3

« Results »

3.1 MDA-MB-231 Breast Cancer Cell Line Comprises Cells with
High Levels of HA Binding That are Resistant to
Doxorubicin
Veiseh et al.25 previously showed that the MDA-MB-231 and other human breast cancer cell
lines contain subpopulations that either bind high (HAhigh) or low (HAlow) levels of HA. HAhigh
subpopulations isolated from MDA-MB-231 parental cells by FACS display significantly higher
local invasion and lung micrometastases in vivo but proliferate more slowly in vitro and as
xenografts in vivo than HAlow or parental cells. These results raise the possibility that HAhigh
subsets are more resistant to chemotherapy than HAlow since slow proliferation allows cells to
escape death from traditional chemotherapeutic agents such as doxorubicin, which
predominantly acts on rapidly proliferating cells98, 175-178. To begin to address this possibility, I
first attempted to repeat the results of Veiseh et al.25, who sorted MDA-MB-231 breast cancer
cells into the above two subpopulations using an Alexa Fluor647 HA probe (F-HA probe). I
prepared the F-HA probe (see section 2.2) and showed that this permitted the isolation of HAlow
and HAhigh MDA-MB-231 subpopulations by FACS similar to that reported by Veiseh et al.25
(Figure 3.1). The HAlow gate was set based on the corresponding unstained control sample
(Figure 3.1 A, B). In all experiments, with varying frequencies, a small but reproducible
population of cells separated from the main population/cluster of stained cells which was gated
as the HAhigh cells (Figure 3.1 B). Each of HAlow and HAhigh subpopulations was composed of 58% of the total population. The post-sorting purity of each HAlow and HAhigh populations varied
between 82-98% (Figure 3.1 C, D). Both HAhigh and HAlow subpopulations were then analyzed
for their differences in proliferation.
The proliferation of HAlow and HAhigh subpopulations in vitro was measured by an alamarBlue
assay. In agreement with the results of Veiseh et al.25, the FACS-isolated HAhigh cells exhibited

37

approximately 57% lower proliferation than HAlow cells in 2D culture (Figure 3.2), which was
statistically significant (P<0.05).
I, therefore, next assessed the resistance of these two subpopulations to chemotherapy. I chose
doxorubicin as a chemotherapeutic reagent since it is often used in breast cancer treatment179-182.
Cell viability was determined in fluorescence units and was plotted against doxorubicin
concentration after exposure of cells to increasing concentrations of the drug in order to
determine the half maximal inhibitory concentration (IC50), which is a measure of drug efficacy,
The IC50 for HAhigh cells was four-fold higher than for HAlow cells (HAhigh IC50: 0.08 µM, HAlow
IC50: 0.02 µM, p<0.05) (Figure 3.3). These results show that HAhigh cells are less sensitive to
doxorubicin than HAlow cells.

Side Scatter

Cell Number

(A) Unstained MDA-MB-231

Log Fluorescence

Log Fluorescence

(B) Stained MDA-MB-231
HAhigh

HAlow

HAhigh

AF647-HA Log Fluorescence
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HAlow
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Figure 3.1. Isolation of MDA-MB-231 cell subpopulations using fluorescent HA binding levels.
Single cells (minimum of 1×106 cells in 1 mL PBS) were exposed to Alexa Fluor647-HA probe for 45
minutes on ice and sorted using FACS. The cell sorting flow cytometry histograms (Left) and dotplots
(Right) represent (A) unstained (B) stained (C) post sort low (HAlow) and (D) post sort high (HAhigh)
fluorescence MDA-MB-231 cells. Fluorescence intensity is shown on the x-axis and the number of
events (histograms)/side scatter (dotplots) on the у-axis. F-HA–binding profile spans from 0 to 10 5
fluorescent units. Each red boxed area shows 5-8% selection of the total parental line. Post sort purity
of HAlow and HAhigh cells is 96.6% and 83.6%, respectively.
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*

Figure 3.2. HAhigh cells proliferate slower than HAlow cells.
Cells were plated at 1000 cells per well in 96-well plates for 72 hours and incubated with alamarBlue
reagent for 4 hours before reading fluorescent at 590 nm. Fluorescence intensity was proportional to the
number of viable cells. Mean ± SEM; n=8 replicates, *p<0.05 as determined by Student’s t-test. The
data represent one of 3 experiments performed with similar results.
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Figure 3.3. IC50 of HAhigh cell treated doxorubicin was four-fold higher than for HAlow cells.
Cells were plated at 1000 cells per well in 96-well plates and 24 hours later treated with doxorubicin
for 72 hours and incubated with alamarBlue reagent for 4 hours before reading the fluorescent signal at
590 nm. Fluorescence intensity was proportional to the number of viable cells and the number of viable
cells. Mean ± SEM; n=8 replicates. The data represent one of 3 experiments with similar results. IC50
values, the concentration of doxorubicin which kills 50% of cells, were determined via nonlinear
regression using GraphPad Prism 4.0 software. HAlow cells with IC50: 0.02 µM were more sensitive to
doxorubicin compared to HAhigh cells with IC50: 0.08 µM (P<0.05).
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The characteristics of HAhigh tumor cells including their slow proliferation, increased aggression
and resistance to chemotherapy resemble the phenotype of “cancer stem cells” or “tumorinitiating cells” that have been identified in breast cancers183, 184. Notably parental MDA-MB-231
tumor cells exhibit a CD24-CD44+ surface phenotype that was used by Al-Hajj et al.185 to
prospectively isolate stem-like cells from primary tumours and pleural effusions186-188. A
complementary approach for identifying stem-like cells is measuring functional activity of
aldehyde dehydrogenase (ALDH), an enzyme involved in stem cell self-protection169,

189

. In

order to further characterize the nature of the HAhigh subsets, I first assessed HAhigh and HAlow
cells for functional activity of ALDH, and then quantified cell surface display of prospective
cancer stem cell markers CD44/CD24 in ALDH+ HAhigh and ALDH+ HAlow subpopulations.
There was no significant difference in the proportion of ALDH+ CD44+ or CD24- cells in either
subpopulation HAhigh (80.4%) and HAlow (88.8%) subpopulations (Figure 3.4 A, C). Also, the
proportions CD44+/CD24- cells in ALDH+ HAhigh and ALDH+ HAlow subpopulations were not
significantly different (99.8% and 99.7%, respectively) (Figure 3.4 B, D).
Collectively, these results show that slowly proliferating HAhigh cells do not appear to be tumorinitiating cells according to the currently accepted definition, high ALDH activity and CD24CD44+ surface phenotype, although they share chemoresistant behavior with tumor-initiating or
cancer stem cells.
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Figure 3.4. HAhigh and HAlow subpopulations do not display significant differences cancer-stem-cell
markers (ALDH+ CD44+ CD24-).
Subpopulations of HAhigh and HAlow cells were separated, then those with elevated ALDH display were
selected for subsequent analysis of surface CD44 and CD24 levels. (A, C) Flow cytometry dot plots of
ALDH activity in sorted HAhigh and HAlow subpopulations. Cells which fell within the ALDH+ region
were considered to represent subpopulations of cells with enhanced ALDH activity relative to the rest of
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the cell population. (B, D) Flow cytometry dot plots of CD44-PE Cy7 versus CD24-PE expression in
ALDH+ HAhigh and ALDH+ HAlow subpopulations. Cells which fell within the square region Q3 were
considered to express the phenotype of interest (CD44+CD24-). A total of at least 0.5×106 cells of each
single- (ALDH or CD24 or CD44), double- (ALDH and CD24, ALDH and CD44, CD24 and CD44), or
triple-stained (ALDH, CD44, and CD24) and unstained groups was used. A minimum of 20,000 events
was collected per sample.
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3.2 HA Synthase 2 Expression and Activity is increased in
HAhigh compared to HAlow Cells
To begin to identify potential mechanisms for the observed differences in proliferation and
doxorubicin sensitivity, I performed a genome-wide mRNA expression profile of HAhigh and
HAlow subpopulations using Human Gene 2.0 ST arrays. A comparison of the transcriptome
expression patterns (more than 53,000 genes) between HAhigh and HAlow unexpectedly revealed
only six significant (p<0.05) differences in gene expression levels (Table 3.1).
To examine the clinical relevance of the genes (RNU5A-1, PTGES, METTL7A, PGA3,
MIR4655, and HAS2) whose expression levels were significantly altered in HAhigh cells
compared to HAlow cells (Table 3.1), I made use of data from a METABRIC dataset that was
available in the cBioPortal database173, 174. I investigated genetic alterations and genome-wide
mRNA expression of the mentioned genes in a cohort of 2509 cases of human breast cancer
tumors in the METABRIC study and compared overall survival of patients with and without
alterations in the query genes173, 174. There was no identified alteration in the RNU5A-1 gene in
the dataset. The result showed that the gene set of PTGES, METTL7A, PGA3, MIR4655, and
HAS2 and their mRNA expression were altered in 33% (824/2509) (Figure 3.5 A). The only
genes associated with poor outcome were HAS2 and PGA3 (log-rank test, p<0.05) (Figure 3.5 B,
C). Alterations in HAS2 (Figure 3.6) were associated with shorter overall survival in a subgroup
of 412 breast cancer cases treated with chemotherapy from the METABRIC dataset (log-rank
test, p<0.05).
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Table 3.1. Genes are differentially expressed in HAhigh vs. HAlow subsets.
Gene
Symbol

Protein/RNA

Protein/RNA Function

Fold Change in
high

name

HA

P-value

low

vs. HA

mRNA
RNU5A-1

U5A

small

Involved in splicing of introns from primary

1

genomic transcript, and the regulation of

nuclear
RNA

1.746

0.0152

1.657

0.0182

1.558

0.0375

1.518

0.036

-1.609

0.0149

1.542

0.0003

RNA polymerase II or other transcription
factors and in the maintenance of telomeres

PTGES

Prostaglandin

Isomerase that catalyzes the conversion of

E synthase

PGH2 into the more stable prostaglandin E2
(PGE2).

METTL7A

PGA3

Methyltransfer

Catalysis of the transfer of a methyl group to

ase like 7A

an acceptor molecule

Pepsin A-3

A

protease

specificity;

with

particularly

although

bonds

broad

involving

phenylalanine and leucine are preferred,
many others are also cleaved to some extent.
MIR4655

MicroRNA

MicroRNAs

are

involved

in

post-

4655

transcriptional regulation of gene expression
in multicellular organisms by affecting both
the stability and translation of mRNAs.

HAS2

HA synthase 2

Catalyzes the addition of GlcNAc or GlcUA
monosaccharides to the nascent hyaluronan
polymer.

Genome-wide mRNA expression profiling was performed using Human Gene 2.0 ST arrays shows
only 6 genes are significantly up/downregulated between HAhigh and HAlow, p<0.05. Three technical
replicates of RNA samples were used for mRNA transcriptome profiling.
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Cases with alterations in PGA3
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Cases without alteration in HAS2
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Figure 3.5. Alterations in HAS2 and PGA3 genes are associated with shorter overall survival in
breast cancer patients.
(A) Gene copy-number calls at the PTGES, METTL7A, PGA3, MIR4655, and HAS2 loci and their
mRNA expression status (up/down regulation) are depicted for 2509 primary breast tumor samples
(Amplification = filled red box; deep deletion = filled blue box; mRNA upregulation = red outline;
mRNA downregulation = blue outline). Overall survival Kaplan–Meier curve of 2509 breast cancer
patients harboring (B) HAS2 and (C) PGA3 alterations (Logrank Test P-Value< 0.05). Data derived
using the METABRIC study from cBioPortal.org173, 174.
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Surviving

Cases with alterations in HAS2
Cases without alteration in HAS2
Logrank Test P-Value: 0.0280

Months survival

Figure 3.6. Alterations in HAS2 gene are associated with shorter overall survival in breast cancer
patients receiving chemotherapy.
Overall survival Kaplan–Meier curve of 412 chemotherapy-treated breast cancer patients harboring
HAS2 alterations (Logrank Test P-Value<0.05). Data derived using the METABRIC study from
cBioPortal.org173, 174.
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Therefore, I focused on assessing of HAS2 expression and activity in HAhigh vs. HAlow subsets
because first, its mRNA expression level showed a significant increase in HAhigh vs. HAlow cells
(Table 3.1) and second, its genetic and transcriptional alterations were associated with shorter
overall survival in BCa patients treated with chemotherapy. Moreover, HAS2 and its product, the
polysaccharide HA, have been linked to TNBC aggression and chemoresistance23, 190-194.
To validate the array observation, I performed real-time quantitative RT-PCR on RNA isolated
from HAhigh and HAlow cells and measured the expression of HAS2. RT-PCR results revealed a
significant upregulation of HAS2 in HAhigh vs. HAlow subsets (p<0.05) (Figure 3.7).
Since the expression of many genes including HAS2 is regulated at the protein level195-198 and
post-transcriptional changes modulate HAS2 distribution and consequently, its activity,
immunofluorescence (IF) staining of HAS2 protein was performed to determine the expression
and subcellular localization of HAS2 in HAhigh and HAlow subpopulations. Although there are
small differences in HAS2 mRNA expression, HAS2 protein levels were increased
approximately 2-fold in HAhigh cells compared to HAlow cells (P<0.05) (Figure 3.8 and figure
3.9). Interestingly, in HAhigh cells, HAS2 aggregated at the cell membrane in approximately 90%
of cells; whereas HAS2 is largely distributed in cytoplasmic vesicles in approximately 90% of
HAlow cells (Figure 3.9).
Since plasma membrane residence of HAS2 is required for its synthetic activity199, I next
quantified the synthesis of HA in HAhigh and HAlow subpopulations. As expected from the
membrane localization of HAS2, HAhigh cells show an approximately three-fold higher amount
of secreted HA than HAlow cells due to higher expression and activation of HAS2 (Figure 3.10).
These results show that HAhigh cells express higher levels of HAS2 mRNA, protein and synthase
activity than HAlow cells. HA has previously been linked to multidrug pump activity143, 145, 200, 201.
Since this mechanism could account for the increased resistance of HAhigh cells to doxorubicin,
this possibility was next assessed.

Relative expression
ratio HAS2/GAPDH
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Figure 3.7. HAhigh cells displayed significantly enhanced HAS2 expression compared to HAlow cells.
mRNA expression of HAS2 in HAhigh and HAlow samples was validated by quantitative real-time RT-PCR
analysis. Reverse transcription was performed using total RNA isolated from three independent samples.
Mean ± SEM; n=6 replicates, *p<0.05 as determined by Student’s t-test. The data represent one of 2

Fluorescence Intensity

experiments performed with similar results.

Figure 3.8. HAS2 protein level is increased in HAhigh cells.
Cells were plated at 2000 cells per fibronectin-coated coverslip in 24-well plates for 24 hours and stained
for HAS2 protein. Immunofluorescence images were captured (>40 per group) and fluorescence intensity
which is proportional to HAS2 protein expression was quantified using ImageJ software. Mean ± SEM,
*P<0.05 as determined by Student’s t-test.
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Figure 3.9. HAS2 protein localizes to the cell membrane in HAhigh cells to a greater extent than in
HAlow cells.
In immunofluorescence images, HAS2 protein (shown in green) shows 2-fold greater intensity in HAhigh
than HAlow cells. Also, HAS2 is more localized (approximately 90% of cells) in the plasma membrane
(shown by arrows) for HAhigh cells and the cytoplasm (shown by arrows) for HAlow cells.

51

Figure 3.10. HAhigh cells produce higher levels of HA than HAlow cells.
Culture media was collected 48 hours after plating and the amount of secreted HA was quantified by
ELISA. Results were normalized to the number of cells. Mean ± SEM; n=8 replicates, *p<0.05,
Student’s t-test was used to determine statistical significance. The data represent one of 2 experiments
with similar results.
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3.3 Intracellular Doxorubicin Accumulation and Distribution Is
Similar in HAhigh and HAlow Cells
Decreased effectiveness of chemotherapy drugs can be due to several reasons including
decreased access to or uptake of drugs, activation of repair and detoxification mechanisms and
increased drug export136. Doxorubicin easily enters cells through passive diffusion and is
pumped out of cells by ATP-dependent efflux pumps, such as P-glycoproteins. HA promotes
drug resistance by both decreasing drug uptake and increasing drug efflux. The HA coat provides
a physical barrier that can decrease drug uptake202. HA increases drug efflux by binding to CD44
on tumor cell surface and regulating expression of drug transporters or mediating their
stabilization in the plasma membrane, depending upon the cancer cell type22, 143, 200. The best
approach to determining if HAhigh cells exhibit altered multidrug pump activity is to expose
subsets to doxorubicin and compare abilities to export this fluorescent drug by monitoring
intracellular accumulation. To compare the net uptake and efflux of doxorubicin in HAlow cells
with HAhigh cells, I measured intracellular doxorubicin related fluorescence intensity by both
flow cytometry (Figure 3.11 A) and confocal imaging (Figure 3.11 B) following 2 hours of
treatment with the drug in vitro. The net uptake and efflux of doxorubicin by HAhigh cells was
not detectably different compared to HAlow cells (Figure 3.11 A, B). Confocal cell images
showed that in both HAhigh and HAlow subpopulations doxorubicin similarly accumulated in the
nuclei (p>0.05) (Figure 3.11 B). These results suggest that the greater doxorubicin sensitivity of
HAlow cells was not due to differences in import or export of the drug.
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Figure 3.11. Intracellular doxorubicin accumulation and distribution is not significantly different
in HAhigh and HAlow subpopulations.
(A) Flow cytometric analyses of HAhigh and HAlow cells show intracellular doxorubicin accumulation
was not significantly different, P<0.05. (B) In vitro fluorescence microscopy images (>40 per group)
high

show HA

low

and HA

cells at 2 hours after doxorubicin treatment. In both subpopulations,

doxorubicin is in both nucleus and cytoplasm, but predominantly nucleus. Intracellular fluorescence
intensity, which is a measure of doxorubicin accumulation in cells, was quantified by ImageJ software.
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The effect of HA on chemoresistance has also been linked to other mechanisms. HA alters cell
proliferation differently depending on its molecular weight and concentration203,

204

. For

example, high molecular weight HA such as used for synthesizing the F-HA probe reduces
proliferation of some cells205, 206, and since chemotherapeutic drugs such as doxorubicin target
rapidly proliferating cells, slowly proliferating cells survive98, 175, 176. Therefore, to determine if
HA is in fact directly supporting chemoresistance to doxorubicin, its synthesis was inhibited. To
inhibit HA synthesis, I used 4-Methylumbelliferone (4-MU) which is extensively used in
experimental models of cancers including TNBC to block HA synthesis207, 208. 4-MU suppresses
HA synthesis by both depletion of cellular UDP-glucuronic acid, HAS and other
glycosyltransferases’ precursors, and downregulation of HAS2 and/or HAS3 in tumor cells209. It
appears 4MU selectively blocks plasma membrane-located HAS209 and not other Golgi-located
glycosyltransferases because210-212 because 4MU does not accumulate in the Golgi, where other
glycosyltransferases are primarily located.
4MU reduced HAhigh and HAlow cell viability in a dose-dependent manner (Figure 3.12). 4-MU
(2.0 mM) exhibited the greatest effect on HAhigh and HAlow cell viability (44.3 and 18.3%,
respectively, p<0.05), following 24 hours of 4MU treatment. HAhigh cells were more sensitive to
4MU than HAlow cells. However, the amount of HA released into the culture medium did not
decrease in the presence of 4-MU at any concentration (Figure 3.13) and I could not exclude that
4MU was affecting cell viability via an HA-independent mechanism209,

213

. Therefore, I

concluded that inhibiting HA synthesis was not an option for these particular cells. Furthermore,
inhibition of HAS2 through knockdown (small interfering RNA) or knockout (CRISPR-Cas9) is
challenging due to the ability of HAS1 or 3 to compensate for HAS2 loss214-216. Since HA acts on
cell proliferation by binding to HA receptors such as CD44 and RHAMM to activate signaling
pathways controlling cell proliferation90, 124, 217-223, I next considered interrupting HA signaling
by blocking these receptors rather than by blocking hyaluronan synthases.
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Figure 3.12. Treatment of HAhigh and HAlow cells with 4-MU reduced cell viability.
HAhigh and HAlow cells were plated at 2000 cells per well in 96-well plates and 24 hours later treated with
4MU for 24 hours and incubated with alamarBlue reagent for 4 hours before reading the fluorescent
signal at 590 nm. Fluorescence intensity was proportional to the number of viable cells. Mean ± SEM;
n=8 replicates, *p<0.05 as determined by Student’s t-test. The data represent one of 3 experiments with
similar results.
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Figure 3.13. 4MU did not inhibit HA synthesis in HAhigh to the level of HA in HAlow cells.
Culture media was collected 24 hours after treating the HAhigh and HAlow cells with 4MU and the amount
of secreted HA was quantified by ELISA. Results were normalized to the number of cells. Mean ± SEM;
n=8 replicates. The data represent one of 2 experiments with similar results.
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3.4 RHAMM Cell-Surface Display Is Higher in HAhigh Compared
to HAlow Cells
Since blocking HA production to directly assess its role in chemotherapy was not
straightforward, I next assessed if blocking HA receptor signaling affected sensitivity to
chemotherapy. In order to decide between CD44 and RHAMM, I first identified which of these
receptors was most highly expressed/displayed by the HAhigh subpopulation. This approach
would also allow me to identify aberrant HA receptor signaling involved in TNBC aggression,
which may contribute to TNBC chemoresistance and which may identify suitable candidates for
targeted therapy, which is currently lacking in TNBC224. Previous studies by Turley and
others156, 225 had shown that MDA-MB-231 cells express high levels of the HA receptors CD44
and RHAMM, which strongly activate the Raf/MEK/ERK pathway promoting motility and
proliferation156. This association is particularly relevant to TNBC because MEK-ERK1/2
signaling is linked to aggressive, chemoresistant TNBC162. For these experiments, I performed a
multiplexed flow cytometry analysis that allowed me to evaluate the cell surface signature using
a combination of F-HA, and immunofluorescence conjugated anti-CD44 and anti-RHAMM
antibodies. Results showed that CD44 is similarly displayed on both HAhigh and HAlow
subpopulations but high RHAMM display was unique to HAhigh cells (Figure 3.14). RHAMM is
a multifunctional protein the expression of which is increased in aggressive breast cancers and
TNBC25, 89, 132, 218, 226. It has been reported that RHAMM regulates cell migration and metastatic
growth, and contributes to chemoresistance218,

227

. Moreover, genetic alterations in HMMR

beside HAS2 and PGA3 genes were associated with shorter overall survival rate in a subgroup of
chemotherapy treated patients from the METABRIC dataset (Logrank Test P-Value
<0.05)(Figure 3.15). These reports and analyses as well as my demonstration of high cell surface
RHAMM display in HAhigh subpopulations led me to assess the consequence of blocking
RHAMM function on MDA-MB-231 cells proliferation and therapy resistance.
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Figure 3.14. RHAMM cell-surface display was higher in HAhigh than HAlow cells.
Cell surface coexpression of RHAMM and CD44 in HAhigh and HAlow subpopulations was compared
using triple staining with F-HA to detect HA binding levels, anti-RHAMM and anti-CD44 antibodies to
detect RHAMM and CD44 display, respectively. A total of at least 1×106 cells of each single- (F-HA or
RHAMM or CD44), double- (F-HA and RHAMM, F-HA and CD44, RHAMM and CD44), or triplestained (F-HA, CD44, and RHAMM) and unstained groups was used. Triple-color flow cytometry dot
plot shows both HAhigh and HAlow subpopulations display a similar range in levels of CD44; however,
RHAMM display is higher in HAhigh compare to HAlow cells. The dashed square represents HAhigh cells
expressing higher levels of RHAMM cell surface.
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Figure 3.15. Alterations in HMMR, HAS2, and PGA3 genes is associated with shorter overall
survival in breast cancer patients receiving chemotherapy.
Overall survival Kaplan–Meier curve of 412 chemotherapy-treated breast cancer patients harboring
HMMR, HAS2, and PGA3 alterations (Logrank Test P-Value<0.05). Data derived using the
METABRIC study from cBioPortal.org173, 174.
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3.5 Cell Surface
Proliferation

RHAMM

Modulates

MDA-MB-231 Cell

Previous studies have reported that RHAMM mediates HA-stimulated cell proliferation and
migration through the Raf/MEK/ERK pathway signaling227, 228. To begin to assess the role of cell
surface RHAMM in chemoresistance, I showed that blocking cell surface RHAMM signaling
using rabbit polyclonal function blocking anti-RHAMM antibody significantly suppressed
HAhigh but not HAlow cells proliferation (Figure 3.16), confirming the role of extracellular
RHAMM in modulating of HAhigh cell proliferation. Previous analyses have shown that this
antibody specifically affects RHAMM function in that it inhibits migration of RHAMM+/+ but
not RHAMM- /- cells97. Since the antibody also did not significantly affect the proliferation of
HAlow cells that display very low levels of surface RHAMM, its effect on the proliferation of
HAhigh cells is likely to be specific. To confirm and extend this observation, the effect of
RHAMM deletion on MDA-MB-231 cell proliferation was investigated. RHAMM expression
was deleted in MDA- MB- 231 cells using CRISPR/Cas9 gene editing. CRISPR/Cas9 targeting
RHAMM was designed to delete exons 3 and 6 in the RHAMM gene of MDA-MB-231 cells.
Clone H8 that did not express RHAMM mRNA or protein was isolated (Figure 3.17 A).
RHAMM-/- MDA-MB-231 cells were a kind gift from Dr. James B. McCarthy (University of
Minnesota, Minneapolis, MN). AlamarBlue assays showed that RHAMM-/- MDA-MB-231 cells
proliferated more slowly than RHAMM+/+ cells (Figure 3.17 B, C).
Next, I tested RHAMM-/- and RHAMM+/+ MDA-MB-231 cells sensitivity to doxorubicin. The
IC50 was approximately two-fold higher in RHAMM-/- MDA-MB-231 cells than RHAMM+/+
MDA-MB-231 cells (RHAMM-/- MDA-MB-231 IC50: 0.05 µM, RHAMM+/+ MDA-MB-231
IC50: 0.02 µM, P<0.05) (Table 3.2) showing RHAMM+/+ MDA-MB-231 cells were more
sensitive to doxorubicin than RHAMM-/- MDA-MB-231 cells. Collectively, these results suggest
that HA binding and RHAMM mediate resistance to doxorubicin and this correlates with the
regulation of cell proliferation.
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Figure 3.16. Blocking cell surface RHAMM function significantly inhibited HAhigh but not HAlow
cell proliferation.
Cells (96K cells/96 well plates) were plated and 4 hours later exposed to a single dose (1:20) of rabbit
polyclonal antibody against exon 3 RHAMM for 72 hours and incubated with alamarBlue reagent for 4
hours before reading absorbance (590 nm). Mean ± SEM; n=8 replicates, *P<0.05 using Student’s t-test.
The data represent one of 2 experiments with similar results.
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Figure 3.17. RHAMM-/- cells grew significantly more slowly than RHAMM+/+ MDA-MB-231
cells.
A) Western blot validation of RHAMM deletion (in clone 8) using the CRISPR/CAS-9 gene editing
system. RHAMM-/- MDA-MB-231 cells obtained from Dr. James B. McCarthy laboratory
(University of Minnesota, Minneapolis, MN). B, C) RHAMM-/- cells grew significantly more slowly
than RHAMM+/+ MDA-MB-231 cells. Cells were plated at 1000 cells per well in 96-well plates and
incubated with alamarBlue reagent for 4 hours before reading absorbance (590 nm) at 8, 24, 48, 72,
and 96 hours following plating. Mean ± SEM; n=8 replicates, *P<0.05 using Student’s t-test. Figure
C shows % cell proliferation inhibition in RHAMM-/- compared to RHAMM+/+ MDA-MB-231 cells.
The data represent one of 3 experiments with similar results.
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Table 3.2. IC50 of RHAMM-/- MDA-MB-231 cell treated with doxorubicin was 2.5-fold
higher than for RHAMM+/+ MDA-MB-231 cells.
RHAMM-/- MDA-MB-231 IC50 0.05 µM
RHAMM+/+ MDA-MB-231 IC50 0.02 µM
P-value
<0.0001
Cells were plated at 1000 cells per well in 96-well plates and 24 hours later treated with doxorubicin for
72 hours and incubated with alamarBlue reagent for 4 hours before reading the fluorescent signal at 590
nm. Fluorescence intensity was proportional to the number of viable cells and the number of viable cells.
Mean ± SEM; n=6 replicates. The data represent one of 2 experiments with similar results. IC50 values,
the concentration of doxorubicin which kills 50% of cells, were determined via nonlinear regression using
GraphPad Prism 4.0 software. RHAMM+/+ MDA-MB-231 cell with IC50: 0.02 µM were more sensitive to
doxorubicin compared to RHAMM-/- MDA-MB-231 cell with IC50: 0.05 µM (P<0.05).

3.6 RHAMM Modulates Intracellular Distribution of Activated
ERK1/2
Cell surface RHAMM is required for formation of CD44-ERK1/2 complexes, and together with
intracellular RHAMM sustains activation of the MEK-ERK1/2 signaling. Therefore, I
determined the total activated ERK1/2 (Phospho-ERK1/2 or pERK1/2), the main component of
the pathway, in whole cell lysates of RHAMM-/- and RHAMM+/+ MDA-MB-231 cells by
ELISA. There was no significant difference in the specific ERK1/2 activity (levels of pERK1/2
normalized against the total ERK1/2) in RHAMM+/+ MDA-MB-231 cells compared to
RHAMM-/- MDA-MB-231 cells (p>0.05). However, I tested the level of active ERK1/2 per cell
using immunofluorescent staining of p-ERK1/2. RHAMM+/+ MDA-MB-231 exhibited higher
ERK1/2 activity per cell compared to RHAMM-/- MDA-MB-231 cells (p<0.05) (Figure 3.18).
Since RHAMM is required for nuclear translocation of pERK1/291, 97, I quantified the nuclear
accumulation of pERK1/2 of RHAMM-/- and RHAMM+/+ MDA-MB-231 cells using
immunofluorescence staining of p-ERK1/2 (Figure 3.19). Approximately 75% of RHAMM+/+
MDA-MB-231 showed nuclear accumulation of pERK1/2 compared to 35% of RHAMM -/-
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MDA-MB-231 cells (p<0.05). These results show that RHAMM expression is primarily
affecting trafficking of pERK1/2 into the nucleus of MDA-MB-231 cells.

Figure 3.18. RHAMM-/-MDA-MB-231 cells exhibit lower ERK1/2 activity than RHAMM+/+MDAMB-231 cells.
Cells were plated at 2000 cells per fibronectin-coated coverslip in 24-well plates for 24 hours and
stained for pERK1/2 protein. Immunofluorescence images were captured (>20 per group) and
fluorescence intensity which is proportional to pERK1/2 protein expression was quantified using
ImageJ software. Mean ± SEM, *P<0.05 as determined by Student t-test.
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Figure 3.19. pERK1/2 protein localize in the nuclei in RHAMM+/+MDA-MB-231 cells to a greater
extent than in RHAMM-/-MDA-MB-231 cells.
In immunofluorescence images, the percentage of cells with nuclear pERK1/2 is higher in RHAMM+/+
compare to RHAMM-/- cells (approximately 75% and 35%, respectively).
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3.7 Sensitivity of MDA-MB-231 Cells to MEK1/2 Inhibition
Depends on RHAMM Expression
Since cell surface RHAMM regulates the Raf/MEK/ERK signaling pathway that promotes
aggressive TNBC cell behavior91, 218, 228 and since activation of this pathway is linked to poor
outcome in TNBC159, 229, I asked whether RHAMM expression may affect the sensitivity of these
tumor cells to MEK inhibitors, which are increasingly being investigated as a therapeutic
approach to managing some cancers. RHAMM plays several roles in regulating the ERK1/2
pathway. First, cell surface RHAMM is required for initial activation of ERK1/2 through its
association with transmembrane receptors including growth factor receptors and CD44. As well,
intracellular RHAMM acts as a scaffold protein that directly binds to ERK1 and forms a
complex with ERK2 and MEK191 that sustains ERK activation. PD98059 was initially used to
block ERK1/2 activity since it is a selective inhibitor of MEK1 activation that has been
extensively used to inhibit ERK1/2 activity in a variety experimental tumor cell models230-233.
Results show that PD98059 inhibited HAhigh cell proliferation to a greater extent than HAlow cells
suggesting that HAhigh cells are significantly more sensitive to MEK1/2 inhibition than HAlow
cells (p<0.05) (Figure 3.20). RHAMM deletion in MDA-MB-231 cells resulted in a decrease in
tumor cell sensitivity to trametinib (trade name: Mekinist), an FDA-approved MEK1 kinase
inhibitor for unresectable or metastatic melanoma with BRAF V600E or V600K mutation (a
mutation at nucleotide 600 which converts a valine to a glutamic acid or lysine, respectively),
and metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by
an FDA-approved test234, 235. Thus, trametinib inhibited RHAMM+/+ and RHAMM-/- MDA-MB231 cell proliferation with GI50 values of 0.6 nM and 2.0 nM, respectively (Table 3.3).
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Figure 3.20. HAhigh cells are inhibited approximately two-fold more by PD98059 compared to HAlow
cells.
n=8 replicates, *P<0.05 HAlow and HAhigh cells determined by Student’s t-test. The data represent one of 3
experiments with similar results.

Table 3.3. RHAMM+/+ MDA-MB-231 cells are more sensitive to trametinib than
RHAMM- /-MDA-MB-231.
RHAMM-/- MDA-MB-231 GI50 2.0 nM
RHAMM+/+ MDA-MB-231 GI50 0.6 nM
P-value
<0.0005
The concentration of Trametinib, which suppresses 50% of cell proliferation (GI50), was higher for
RHAMM-/- than RHAMM+/+ MDA-MB-231 cells. trametinib is an FDA-approved MEK inhibitor for
treating advanced melanomas. Mean ± SEM; n=8 replicates. The data represent one of 3 experiments
with similar results. GI50 values were determined via nonlinear regression using GraphPad Prism 4.0
software.
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Chapter 4

4

« Discussion »

Hyaluronan is a major component of the tumor microenvironment in many cancer types and
together with its cell-surface receptors, e.g. CD44 and RHAMM, is actively involved in tumor
progression and development of chemoresistance. The binding of hyaluronan to breast cancer
cell subtypes is heterogeneous25. Findings from the previous study25 showed that tumor cell
subsets that bind the highest levels of HA are highly aggressive in terms of invasion and
metastasis. However, these same subsets proliferate slowly, prompting me to postulate that these
aggressive cells are likely to be resistant to therapies that target proliferating tumor cells.
Here, I present four major findings. Firstly, I verified that the HAhigh subset of MDA-MB-231
BCa cells is significantly less proliferative than the parental or HAlow subsets. Secondly, I
discovered that the HAhigh subset in this tumor cell line is more resistant to doxorubicin, a
routinely used breast cancer chemotherapeutic drug that mainly targets DNA, than the HAlow
subset. Thirdly, and in contrast to the effects of doxorubicin, I find that HAhigh subset is more
sensitive to targeting the MEK-ERK kinase pathway. Fourthly, I discovered that this sensitivity
is controlled by RHAMM expression because knockout of RHAMM makes MDA-MB-231 cells
more resistant to MEK inhibition. My overall conclusions are that the level of HA binding is
linked to chemoresistance while the level of RHAMM display is linked to sensitivity to targeted
therapy (MEK1 inhibition). I propose that these two properties may be useful biomarkers for the
management of TNBC.

4.1 RHAMM as a Prognostic Factor
Chemotherapy and Targeted Therapy

for

Response

to

TNBC is the most lethal subtype of breast cancer due to lack of the effective treatment. It is
resistant to chemotherapy and lacks clinically approved molecularly targeted therapies. The
(intra- and inter-) tumor heterogeneity is a major hurdle to achieve effective treatment. I have
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identified RHAMM as a potential marker for detecting subsets that are resistant to
chemotherapy, but potentially targetable with molecularly directed therapies in clinical
development.
RHAMM is an oncogenic protein that has been implicated in the progression of many cancers
including TNBC89. The oncogenic effects of RHAMM on aggressive behavior like motility and
invasion and resistance to therapy are mainly driven through the Raf/MEK/ERK pathway89. Cell
surface RHAMM binds to HA and associates with CD44 and growth factor receptors. The
resulting complexes, induce activation of the Raf/MEK/ERK pathway89. Intracellular RHAMM
RHAMM binds directly to ERK1, forming complexes with ERK2 and MEK1 and is required for
retention of activated ERK1/2 in the nucleus236.
The Raf/MEK/ERK pathway, a pathway that is deregulated in TNBC, is organized by a variety
of scaffold proteins, including RHAMM237 . These scaffold proteins regulate the activity of the
pathway (positively or negatively), localize its output, increase the efficiency of signal
transmission, and/or isolate the pathway from crosstalk with other MAP kinase pathways.
Intracellular RHAMM is proposed to function as a scaffold protein since it binds directly to

ERK1 and complexes with ERK2, MEK1, and ERK1/2 substrates238. Furthermore, RHAMM as
a scaffold protein is required for the translocation of ERK1/2 to the nucleus in the situations such
as tissue injury responses, in particular in response to serum and PDGF-BB57,
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. ERK1/2

translocation to the nucleus requires phosphorylation by MEK, which causes formation of ERK
dimers. This dimerization facilitates the translocation of activated ERK1/2 into the nucleus. The
cell surface RHAMM in coordination with the intracellular form regulates sustained activation of
MEK1-ERK1/2237. Results of the current study confirm that RHAMM expression is necessary
for nuclear localization of pERK1/2. I found that RHAMM loss attenuated activated ERK1/2 in
nuclei of RHAMM-/- compared to RHAMM+/+ MDA-MB-231 cells. Nuclear localization of
ERK1/2 is required for expression of target genes of the Raf/MEK/ERK pathway that promote
TNBC aggression. Therefore, even though RHAMM does not appear to be essential for
controlling total cellular ERK activity, my results suggest that it is critical for activation and
nuclear retention of ERK1/2 in TNBC cells. Nuclear localization of ERK1/2 is required for
manifestation of its oncogenic properties.
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Although in my study RHAMM loss did not significantly reduce total cellular activated ERK1/2
compared to RHAMM+/+ MDA-MB-231 cells, Wang et al.103 showed that in MDA-MB-231
cells, down-regulation of RHAMM expression by lentivirus-mediated shRNA inhibited total
cellular ERK1/2 activity. This discrepancy in my vs. Wang’s results may be due to the variability
of the results from the same cell line from two different laboratories. These variabilities originate
from differences in cell banks and lots, dissimilarities between the two laboratories’ cell
culturing techniques and materials such as media and serum, as well as genotypic and phenotypic
drift. More importantly, in the current study RHAMM was knocked out using CRISPR-Cas9
method while in the other study it was knocked down using shRNA, which did not completely
inhibit RHAMM expression and thus may not have resulted in the enlistment of compensatory
mechanisms. Furthermore, Wang et al.103 did not look at the distribution of pERK1/2. As it has
been mentioned, RHAMM is not only essential for ERK activation but also is associated with its
cellular distribution.
HAhigh cells are more resistant to doxorubicin than HAlow cells (Figure 3.3). The fact that the
intracellular accumulation of doxorubicin is not different in both HAlow and HAhigh subsets raises
the possibility that HAhigh cells tolerate higher concentration of doxorubicin compared to HAlow
cells. This increased resistance to doxorubicin can be due to increased activation of cell survival
and anti-apoptotic pathways in HAhigh than in HAlow cells. The other possible mechanism
contributing to this effect is the slow proliferation rate of HAhigh cells. The slowly proliferative
RHAMM- /- cells are resistant to doxorubicin consistent with the possibility that proliferation rate
is a key factor in sensitivity to this chemotherapeutic reagent. Doxorubicin targets proliferative
cells and both HAhigh and RHAMM-/- are slow cycling. Therefore, their resistance to DNA
targeting cytotoxic drugs is likely simply due to their slow proliferation.
HAhigh subsets are RHAMMhigh and although some studies predict that RHAMM should promote
proliferation, this is controversial as studies have provided evidence that enriching cells with
extracellular RHAMM reduces cell proliferation134. As well, others have shown that RHAMM
deletion does not affect proliferation per se but rather the orientation of dividing cells. My results
suggest that RHAMM does play a role in the proliferation of MDA-MB-231 cells. However,
although it is likely that the increased accumulation of active nuclear ERK contributes to
RHAMM-mediated proliferation, this was not addressed in my study and others have shown that
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mitotic effects of RHAMM are mediated by unrelated signaling mechanisms. In my genomewide mRNA screen, RHAMM level was not significantly different between HAhigh and HAlow
subpopulations. Since transcription and translation are far from having a linear and simple
relationship, the two subsets might have different levels of RHAMM protein. It is also likely that
HAhigh subsets export RHAMM to the cell surface while HAlow cells do not without altering the
total amount of either mRNA or protein.
Cell surface RHAMM in complex with CD44 and HA causes high basal motility in invasive
breast cancer cells through the Raf/MEK/ERK pathway. Given that RHAMM display was higher
in HAhigh than HAlow cells, the best strategy to target the metastatic and chemoresistant HAhigh
cells was targeting the Raf/MEK/ERK pathway. To suppress this signaling cascade, I chose to
inhibit MEK1/2 for several reasons239, 240. First, MEK inhibitors, unlike other kinase inhibitors,
do not compete with ATP binding, which confers a high specificity. Second, effective targeting
of MEK1/2 is highly specific as it does not have multiple downstream targets (ERK1/2 is its sole
downstream target). Lastly, the most important advantage of inhibiting MEK is that it can be
targeted without knowledge of the exact genetic mutation that results in its aberrant activation240.
Since HAhigh cells are resistant to chemotherapy and sensitive to MEK inhibition, targeting the
Raf/MEK/ERK pathway could prove to be an effective treatment option. However, studies have
shown that MEK-targeted therapies may fail due to activation of cell survival pathways241-243.
Mirzoeva et al.241 showed that MDA-MB-231 cells are particularly susceptible to growth
inhibition by small-molecule MEK inhibitors, CI1040 and U0126. However, there is a cross-talk
between the Raf/MEK/ERK and phosphatidylinositol 3-kinase (PI3K) pathways (Figure 4.1). In
response to MEK inhibition, a negative MEK-EGFR-PI3K feedback loop activates the PI3K
pathway. Because the PI3K pathway is a known promoter of the cell cycle and suppressor of
apoptosis, its activation in response to MEK inhibition could counterpart therapeutically relevant
effects of MEK inhibition. Consistent with their results, another group showed that treatment of
MDA-MB-231 cells with the MEK inhibitor trametinib enhanced the levels of phospho-AKT, an
essential component of the PI3K pathway244. Nonetheless, preclinical studies have shown that
dual targeted inhibition of MEK and PI3K pathways can inhibit cell proliferation and induce
apoptosis in normal and cancer cells239, 241, 245. Several clinical trials are underway to evaluate
this promising combination for various cancer types including TNBC246. For example, targeting
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PI3K and MEK with BYL719 and MEK162, respectively, in advanced solid tumors is being
evaluated in phase Ⅱ clinical trial246.
In this study, I identified the possibility that detection of cell surface RHAMM expression is a
predictive marker for the identification of chemoresistant subpopulations in breast cancer. This is
concordant with other studies that have shown RHAMM is transported to the membrane in
invasive cancer cell lines227, 228. This study also provides evidence that the use of MEK inhibitors
in combination with conventional chemotherapeutic drugs may be an effective pharmaceutical
strategy for treating TNBC.

Figure 4.1. Schematic representation of the Raf/MEK/ERK and PI3K pathway
interconnectivity.
The cross talk between the Raf/MEK/ERK and PI3K pathways in the absence (A) and presence
(B) of MEK inhibitors. There is a negative regulatory feedback loop activating PI3K pathway in
an EGFR-dependent mode in response to MEK inhibition (Figure adapted from Mirzoeva et
al.241).
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4.2 The phenotypic stability of HAlow
Phenotypes

and HAhigh TNBC

The study by Veiseh et al.25 postulates that the HAlow and HAhigh phenotypes are stable, not
dynamic as the phenotype of HAlow cells remained stable after growth in culture for 7 days and
retained these phenotypes following growth in mammary fat pads of immune compromised mice
for 2 months. Furthermore, a study from the Turley and McCarthy (UMN, USA) laboratories has
shown that the HAlow and HAhigh phenotypes in PC3MLN4 prostate cancer cells are stable after
orthotopic growth in prostates for 3 months (manuscript in preparation). Nevertheless, in my
study the purity of these two phenotypes was estimated to be 82-98% and the gradual reversion
of HAhigh subpopulation to a parental phenotype is likely due to overgrowth by contaminating
subpopulations. To establish whether the phenotype is stable in culture, complementary
purification strategies to FACS including cloning by limiting dilution and/or single-cell sorting
methods.

4.3 The Transcriptome of HAlow and HAhigh Cells
Comparison of microarray-based transcriptome profiles between HAhigh and HAlow cells showed
only a few significantly changed genes. Although unexpected, several factors indicate that this
low level of transcriptome change is likely real. First, two of the 5 genes identified in the screen
as increased in the HAhigh subpopulation have been implicated in breast cancer and data mining
show that these are linked to patient survival and poor response to chemotherapy. As well a
similarly low number of changes were observed in the HAhigh subset of PC3MLN4 prostate
tumor cells. This prostate cancer cell subset exhibits a similar aggressive and poorly proliferative
phenotype as MDA-MB-231 TNBC cells. The reasons why HAhigh and HAlow cells exhibit only
small differences an mRNA transcriptome yet have quite markedly different phenotypes is not
clear. Purity could be one issue. However, the Affymetrix mRNA microarray used in my study is
limited in that it does not detect splice variants and it may be that many of the genes responsible
for the two phenotypes of HAhigh and HAlow subsets are variants. E.g. RHAMM and CD44 are
two HA receptors that are subject to alternative splicing which would not be detected by
microarray and which result in different protein activity. As well, proteins are activated by post-
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translational mechanisms and protein stability is also regulated, which are properties not detected
by either RNAseq or Affymetrix arrays and proteome analyses might elucidate more accurately
the signaling changes that are required to generate the two phenotypes. For example, HAS2
protein level is different in the two subpopulations and exhibits different subcellular localization.
My study implicates the role of PGA3 in TNBC chemoresistant and poor outcome. PGA3 is not
well studied in BCa and could be the subject of the future studies.

4.4 Strategies for Increasing the Purity of Isolated HAlow and
HAhigh Subpopulations
This study has further characterized HAhigh and HAlow phenotypes and has shown that the HAhigh
cells with higher HA binding levels, express more HAS2 and RHAMM protein at the plasma
membrane. Therefore, sorting for HAS2 and RHAMM display may yield in isolating
subpopulations with higher purity. Moreover, in the current study, a mixture of different sizes of
HA molecules was used to isolate HAhigh and HAlow cells. Using specific sizes of HA fragments
may also result in higher purity of aggressive subpopulations.

4.5 Significance and Future Studies
Prognostic markers improve the accuracy of risk stratification of cancer patients and provide
important data to optimize therapeutic decisions. The novel findings presented here suggest that
the detection of cell surface RHAMM will aid in predicting the susceptibility of TNBC cells to
targeted therapy, in this case MEK1/2 inhibition. As some studies have shown that inhibition of
MEK results in resistance of the cancer cells by compensatory activation of PI3K pathway,
future studies are required to explore status of PI3K pathway in HAhigh cells exposed to MEK
inhibition.

75

To the best of my knowledge, this is the first RHAMM study related to chemoresistant in TNBC,
suggesting RHAMM as a marker of chemoresistant breast cancer cells. Results of the current
study postulate that the subcellular localization of RHAMM might be more informative than its
mRNA level for evaluating the susceptibility of TNBC cells towards chemotherapy. The
chemoresistant HAhigh cells express higher cell surface RHAMM than the chemo-sensitive HAlow
subpopulation, while the mRNA levels are not significantly different.
To my knowledge, this is the second report that provides evidence that RHAMM regulates
sensitivity to targeted therapy and the first involving TNBC brest cancer. The other study shows
that loss of RHAMM in malignant peripheral nerve sheath tumors increases aurora kinase A
(AURKA) activity and sensitizes tumor cells to AURKA inhibitors247. AURKA, an important
regulator of the cell cycle, is essential for progression through mitosis. Despite the complexity of
RHAMM functions in tumors, this study and the current study both suggest that its levels and
distribution have a diagnostic/prognostic value such as identifying tumor subpopulations that are
sensitive to targeted therapy such as AURKA and MEK inhibitors.

4.6 Limitations
The major limiting factor for performing some experiments was the the low number of sorted
HAhigh and HAlow cells. Each subset was composed of only 5-8% of the total population. The two
sorted subpopulations were not 100% pure, making in vitro expansion of the sorted cells not an
option.
Furthermore, the results of this study are limited due to use of only one TNBC cell line and lack
of patient derived tumors. It will be important to validate the results in additional TNBC cell
lines as well as breast cancer patient samples (e.g. TNBC patient xenografts in immune
compromised mice) in order to draw firm conclusions as to the importance of HAhigh subsets in
TNBC aggression.
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